Pharmaceutical composition for effectively delaying and treating myopia
By applying topical ophthalmic preparations of thioctic acid or thioctic choline esters, the problem of effectively controlling myopia progression in existing technologies has been solved, achieving safe and effective treatment for myopia in children and adolescents.
Patent Information
- Application Number
- PCT/CN2024/094904
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-24
- Filing Date
- 2024-05-23
- Publication Date
- 2024-11-28
AI Technical Summary
Current technologies lack effective and safe drugs for the treatment and control of myopia, especially the progression of myopia in children and adolescents, and traditional methods are difficult to effectively inhibit axial elongation and increase in vitreous cavity length.
Using lipoic acid or lipoic acid choline ester as the main active ingredient, a safe and effective ophthalmic formulation has been developed through local administration to directly act on the eye to inhibit the progression of myopia and control axial elongation.
It significantly inhibits the occurrence and development of myopia, slows down the elongation of the axial length and the increase in the length of the vitreous cavity, and improves the safety and effectiveness of myopia treatment. It is especially suitable for myopia in children and adolescents.
Smart Images

Figure CN2024094904_28112024_PF_FP_ABST
Abstract
Description
A pharmaceutical composition that effectively delays and treats myopia Technical Field
[0001] The present application relates to a pharmaceutical composition for effectively delaying and treating myopia, and in particular to a method for treating myopia using lipoic acid or lipoic acid choline ester, as well as a method and use for controlling the progression of myopia, and provides corresponding drugs or preparations, belonging to the field of medicine. Background Art
[0002] Myopia is the most common refractive error, a condition in which parallel light rays, after being refracted by the eye's refractive system, focus in front of the retina when the accommodation is relaxed. The pathogenesis of myopia is highly complex, involving multiple factors, including genetics, environment, age, intensity of eye use, and even dietary habits. Within the vast literature on the pathogenesis of myopia, many experimental conclusions concerning myopia treatment or induction have been questioned by peer experts, and there are even cases where contradictory results were obtained under similar experimental conditions. This is particularly true in the study of molecular targets for compound intervention in myopia. For example, in an animal model induced by negative lenses, it was found that the cAMP analog 8-Bromo-cAMP can effectively treat myopia (Rachel Ka Man Chun et al., Cyclic Adenosine Monophosphate Activates Retinal Apolipoprotein A1 Expression and Inhibits Myopic Eye Growth, Invest Ophthalmol Vis Sci., 2015 Dec; 56(13): 8151-7.), while another study also used a cAMP analog not only without any therapeutic effect on myopia, but also induced myopia (Fuxin Zhao et al., Declines in PDE4B activity promote myopia progression through downregulation of scleral collagen expression, Exp Eye Res., 2021 Nov;212:108758.); Actual experiments have found that typical antioxidants such as vitamin C (ascorbic acid) have no therapeutic effect in wild-type mouse myopia models. In contrast, in mice with retinitis pigmentosa caused by a gene mutation (rd10), vitamin C can inhibit form-deprivation-induced myopia (Erica Landis et al., Ascorbic acid, and not L-DOPA, protects against form-deprivation myopia in retinal degeneration mouse models., IOVS, ARVO Annual Meeting Abstract, September 2016, Volume 57, Issue 12). Taking atropine sulfate, which has been approved for marketing in China, as an example, under the same treatment population and active ingredient, although both low and high concentrations of atropine have an inhibitory effect on the occurrence and progression of myopia during clinical administration, high concentrations of atropine show a "drug withdrawal rebound" phenomenon.These animal disease model data and clinical studies continue to remind researchers that it will be difficult to predict the final efficacy of myopia treatments by attempting to conduct experiments based solely on principled assumptions or speculations. This is because the mechanism of myopia is still unclear and therefore difficult to prevent and control.
[0003] In addition to insufficient basic research, people have also found that the cell biological mechanisms involved in myopia are different from those in other tissues or organs. For example, the scleral collagen content, a key indicator in myopia treatment research, is upregulated when other tissues in the body transdifferentiate from fibroblasts to myofibroblasts (Shan Jiang et al., Inhibition of TRPC6 suppressed TGFβ-induced fibroblast-myofibroblast transdifferentiation in renal interstitial NRK-49F cells., Exp Cell Res., 2022 Dec 1; 421(1): 113374. and Kazuya Kusama et al., PGE2 and Thrombin Induce Myofibroblast Transdifferentiation via Activin A and CTGF in Endometrial Stromal Cells., Endocrinology. 2021 Dec 1; 162(12): bqab207.), and the occurrence of this transdifferentiation is accompanied by a decrease in collagen during the development of myopia (Hao Wu et al., Scleral hypoxia is a target for myopia control., Proc Natl Acad Sci USA., 2018 Jul 24;115(30):E7091-E7100.). Therefore, in attempts to treat myopia, it is difficult to draw on research results from other organs or other diseases, because the structures and functions of different organs vary greatly, and the cellular signaling pathways of different diseases are very different. In addition, due to the complex structure of the mammalian eye, such as the presence of biological barriers such as the cornea and sclera, the development of myopia treatment drugs and the use of drugs to prevent and control myopia are very challenging.
[0004] In addition, there are many types of myopia, including complex myopia or myopia in people of different ages, such as pathological myopia, myopia with a diabetic basis or directly caused by high blood sugar, myopia in the elderly, high myopia, myopia caused by lens or corneal lesions, etc., which usually show different pathological changes or are accompanied by other underlying diseases that affect treatment. Therefore, the clinical treatment methods for complex myopia are also different from those for common myopia. At present, there is a lack of effective and safe drugs for the treatment of myopia, especially for controlling the progression of myopia in children and adolescents. Therefore, there is an unmet clinical need in this field.
[0005] Lipoic acid (Lipoic acid), commonly referred to as α-Lipoic acid, is an eight-carbon fatty acid (such as Formula I) with a disulfide bond. It is both fat-soluble and water-soluble and can be reduced to dihydrolipoic acid in the body. Lipoic acid has two enantiomers, namely R (dextrorotatory)-lipoic acid and S (levorotatory)-lipoic acid. Lipoic acid API intermediates generally include granular lipoic acid, R-lipoic acid, lipoic acid tromethamine salt and 6,8-dichlorooctanoic acid ethyl ester. Among them, R-lipoic acid tromethamine salt has strong stability and high bioavailability. Lipoic acid choline ester (LACE) is a chemically synthesized derivative of α-lipoic acid, which can be further salified in ophthalmic preparations, as described in patent CN108135842A. Several lipoic acid, its optical isomers, its racemates, its solvates, its pharmaceutically acceptable salts or esters, its prodrugs, its metabolites, its related compounds or extracts, or its crystalline compounds have been disclosed in the prior art. These substances can increase the solubility or stability of lipoic acid, but are all considered to have the functions of lipoic acid. Therefore, in this application, they are all considered to be able to treat myopia.
[0006] In the medical field, lipoic acid is mainly used to treat various diseases such as diabetic peripheral neuropathy and neurological complications. In the field of ophthalmic presbyopia treatment, lipoic acid can restore the elasticity of the lens of aging individuals, but LACE failed to reach the primary endpoint of the interim analysis of the Novartis Phase IIb dose range study. In addition, due to its antioxidant capacity, oral lipoic acid has also been used in clinical trials for the treatment of age-related macular degeneration, but its efficacy also did not reach the clinical endpoint (Benjamin J Kim et al., Orally Administered Alpha Lipoic Acid as a Treatment for Geographic Atrophy: A Randomized Clinical Trial., Clinical Trial Ophthalmol Retina., 2020 Sep; 4(9): 889-898.). In the field of food and health care, lipoic acid has been publicly reported as a promising anti-obesity drug.
[0007] Summary of the Invention
[0008] This application unexpectedly discovered a novel use for lipoic acid and demonstrated through repeated experiments that lipoic acid and lipoic acid cholinester can treat myopia and control the onset and progression of myopia. Specifically, lipoic acid is not used as a supplement or auxiliary ingredient in a myopia treatment drug to assist, accompany, or assist other active substances for treating myopia to enhance the therapeutic effect of the active substance (e.g., to allow more of the main drug ingredients to reach the target cells); rather, it is used as the direct active ingredient or primary active ingredient in the treatment of myopia.
[0009] This application demonstrates for the first time that lipoic acid alone has a significant inhibitory effect on myopia progression, and thus it is believed that lipoic acid can effectively treat various types of myopia, including simple myopia or axial myopia (such as children and adolescent myopia), mild or moderate myopia, etc. Compared with the use of lipoic acid to treat elderly myopia, or high myopia, or elderly high myopia, or pathological myopia, the effect of lipoic acid for treating myopia with a continuous decrease in refractive power (such as simple myopia, axial myopia, or axial simple myopia, or low and moderate myopia, or children and adolescent myopia, or progressive myopia, etc.) will be significantly better.
[0010] Lipoic acid and lipoic acid choline ester can also be used to prevent various types of myopia. For example, the use of lipoic acid and lipoic acid choline ester for drug intervention in the progression stage of myopia can prevent and stop the occurrence of myopia in the elderly, high myopia, high myopia in the elderly and pathological myopia.
[0011] This application further studies the concentration, ratio and formulation of lipoic acid or lipoic acid cholinester in drugs or preparations for treating myopia, as well as the frequency of administration of related drugs, combined treatments and other medication methods. Among them, local (ocular) administration is not only safe but also has a therapeutic effect significantly better than that of systemic administration.
[0012] The present application provides the use of lipoic acid or lipoic acid choline ester, or its optical isomers or racemates, or its solvates, or its pharmaceutically acceptable salts or esters, or its prodrugs, or its metabolites, or its related compounds or extracts, or its crystalline compounds, or a combination of these substances, wherein the use satisfies one of the following or two or more of the following conditions simultaneously:
[0013] ①Prevention and / or treatment of myopia and its related symptoms, and / or myopia correction; or
[0014] ② Combined with orthokeratology lenses or other myopia treatment drugs to control the occurrence and development of myopia; or
[0015] ③ For interventional treatment of myopia or delaying the progression of myopia; or
[0016] ④ Inhibit or slow down the elongation of the eye axis and / or the increase in the length (depth) of the vitreous cavity in myopic individuals or individuals with myopia tendency; or
[0017] 5. Prevent, slow down, reduce or treat abnormal development of the eyeball associated with visual impairment; or
[0018] ⑥ Enables an individual to achieve clearer distance vision without wearing lenses or relying on vision correction devices than before and / or than without the use of these lenses or devices; or
[0019] 7. Inhibit, delay or slow down the process or speed of negative refraction in myopic individuals or individuals with myopia tendency; or
[0020] ⑧For preparing a drug, preparation, composition or device, wherein the drug, preparation, composition or device is used to achieve at least one of the uses in the above ①-⑦.
[0021] In some embodiments, the R optical isomer accounts for 50% or more (e.g., 99%) of the total lipoic acid, or its optical isomers or racemates, or its solvates, or its pharmaceutically acceptable salts or esters, or its prodrugs, or its metabolites, or its related compounds or extracts, or its crystalline compounds, or a combination of these substances, or its proportion is less than 50%.
[0022] In some embodiments, the R optical isomer accounts for 50% or more (e.g., 99%) of the total lipoic acid choline ester, or its optical isomer or racemate, or its solvate, or its pharmaceutically acceptable salt or ester, or its prodrug, or its metabolite, or its related compound or extract, or its crystalline compound, or a combination of these substances, or its proportion is less than 50%.
[0023] In some embodiments, the lipoic acid is particulate lipoic acid.
[0024] In some embodiments, the specific content ratio or molar ratio of the two optical isomers may affect the biological activity of lipoic acid, or its optical isomers or racemates, or solvates, or pharmaceutically acceptable salts or esters (such as lipoic acid choline ester), or prodrugs, or metabolites, or related compounds or extracts, or crystalline compounds, or combinations of these substances, such as the therapeutic efficacy for myopia.
[0025] In some embodiments, systemic administration such as oral administration, and / or topical administration (eye drops, eye injections, eye implants, skin creams / creams applied around the eyes or eye ointments), and / or parenteral administration (such as through mucosal administration, transdermal administration, microneedle administration), and / or non-invasive administration (such as administration using eye sprays) is used. Preferably, the systemic administration refers to improved systemic administration.
[0026] In some embodiments, free lipoic acid can be detected in the blood of a myopic individual or an individual prone to myopia after oral administration.
[0027] In some embodiments, the drug, preparation or composition can be an injection, tablet, lyophilized powder injection, capsule, effervescent tablet, chewable tablet, buccal tablet, granule, ointment, syrup, oral solution, aerosol, nasal drop, external preparation, oral preparation, etc.; preferably, it is an ophthalmic dosage form, including but not limited to eye drops (eye drops), eye ointment, eye spray, implant, eye gel, eye patch, eye microsphere, eye sustained-release preparation, periocular injection, intraocular injection; it can also be a regular solution, aqueous solution, unsaturated solution, oil-water mixture, suspension (agent), ointment, lotion, cream, drops, granule, spray, ointment, patch, paste, pill, suppository, emulsion, containing cellulose (such as methylcellulose), polyhydroxy alcohol, cyclodextrin (such as hydroxypropyl-β-cyclodextrin), alkaline cosolvent, dendrimer, nanomaterial, sustained-release material, liposome or any combination thereof.
[0028] In some embodiments, the drug, preparation, or composition comprises distearate phosphatidylcholine, soybean lecithin, octadecylamine, poloxamer 188, sodium chloride, mannitol, mercaptoethanol, tromethamine, sodium sulfite, ethylenediamine, benzyl alcohol, arginine, or any combination thereof. Of course, the drug, preparation, or composition of the present application may not contain any of the substances described in this paragraph.
[0029] In some embodiments, the myopic individual or the individual with a tendency to develop myopia is a child and / or adolescent, preferably a person aged 2 to 30 years old, more preferably a person aged 6 to 18 years old; or a minor, preferably a person whose eyes (eyeballs) are still in the growth and development stage; or a school-age person, preferably a person in grades 1 to 12; or a person whose parents are highly myopic; or a person with insufficient hyperopia reserve.
[0030] In some embodiments, myopia is refractive myopia or axial myopia; congenital myopia (myopia at birth or before school age), early myopia (under 14 years old), late myopia (16-18 years old), late myopia (after adulthood); low myopia (mild myopia), moderate myopia, high myopia (severe myopia); pseudomyopia, true myopia; myopia in children and / or adolescents (preferably aged 2-30 years old, more preferably aged 6-18 years old), myopia in minors, myopia in adults, myopia in the elderly ... Myopia in adults; simple myopia, pathological myopia; axial simple myopia, simple axial myopia; axial myopia in children and / or adolescents (preferably aged 2-30 years, more preferably aged 6-18 years); axial myopia in school-age and preschool-age people; primary myopia, secondary myopia; primary myopia in children and / or adolescents (preferably aged 2-30 years, more preferably aged 6-18 years); or progressive myopia in children and / or adolescents (preferably aged 2-30 years, more preferably aged 6-18 years). The age group is 6-18 years old); curvature myopia, index myopia, astigmatism myopia, positional myopia, tortuosity myopia; axial myopia with continuously negative refractive power; myopia caused by long-term close-range eye use, myopia and pseudomyopia caused by visual fatigue, negative refractive power caused by adverse drug reactions, myopia, myopia caused by reading, myopia caused by using mobile phones and other electronic products, myopia caused by mismatch of refractive media (components), refractive myopia, myopia caused by abnormal refractive development, myopia caused by excessive eye growth. , myopia caused by unhygienic eye use, the focus of distant object imaging falling in front of the retina due to various reasons, myopia with poor or ineffective treatment with atropine, non-complex myopia (such as progressive complex myopia not accompanied by lipid peroxide oxidation POL disorder, non-elderly myopia, or non-high myopia, or keratoconus myopia not related to the Nrf2 / HO-1 signaling pathway, etc.), myopia caused by insufficient outdoor exercise, accommodative tension myopia, children's myopia, infantile myopia, hereditary myopia, and myopia dominated by environmental factors.
[0031] In some embodiments, myopia mainly refers to myopia that is prevalent in healthy young individuals or young people (patients do not have underlying diseases, such as hypertension, hyperlipidemia, hyperglycemia, etc.) rather than high myopia or myopia in the elderly.
[0032] In some embodiments, myopia includes or excludes high myopia or myopia complications caused by high myopia, myopia or myopia complications caused by diabetes (hyperglycemia), myopia or myopia complications caused by lens disease, and / or myopia or myopia complications caused by keratoconus.
[0033] In some embodiments, myopia-related symptoms include complications caused by myopia (especially high myopia): such as floaters, glaucoma, posterior scleral staphyloma, retinopathy, retinal detachment, retinal tear, amblyopia, macular hemorrhage, choroidal neovascularization, choroidal atrophy, macular degeneration or macular disease, visual field loss, progressive or sudden decrease in vision (especially near vision), eye soreness and / or pain, night blindness, astigmatism, blindness, vitreous liquefaction, vitreous opacity, strabismus, frequent blinking, frequent rubbing of eyes, anisometropia, blurred vision when looking at distant objects, needing to squint or partially close the eyelids to see distant objects clearly, headaches caused by eyestrain, difficulty concentrating due to myopia, difficulty seeing when driving, especially at night (night myopia), retinal atrophy and degeneration (hemorrhage and holes), subretinal neovascularization, or eyeball atrophy.
[0034] In some embodiments, myopia-related symptoms include or exclude myopia or myopia-related symptoms induced by hyperglycemia, such as choroidal neovascularization, retinopathy, or macular degeneration in patients with hyperglycemia.
[0035] In some embodiments, the drug, preparation, composition or device further comprises other drugs, compounds or ophthalmic preparations, including but not limited to myopia treatment drugs (such as pirenzepine, muscarinic antagonists, robaxin, indoramine, timolol maleate, epinephrine, pyrazine, pyrimethamine, chlorisondamine, acetylcholinesterase inhibitors, dopamine Agonists, gamma-aminobutyric acid, naloxone, glucagon, homatropine bromide, tretinoin, salidroside, formononetin, etc.), prazosin, vinpocetine, benzalkonium chloride, benzyldamine, benzalkonium chloride, M receptor blockers (such as blockers, antagonists, or inhibitors targeting M2 or M3 receptors), atropine or atropine sulfate, dibazole, polyunsaturated fatty acids (such as DHA, EPA), homatropine, anisodamine (racemic), tropicamide, 7-methylxanthine, niacin, piracetam, salvia miltiorrhiza extract , safflower extract, fish oil, bear bile extract, vitamins, adenosine triphosphate (ATP), smooth muscle relaxants, drugs to prevent vasospasm, non-selective adenylate antagonists, vasodilators, mydriatic components, congestion removal components, eye muscle (such as ciliary muscle) regulation components, anti-(anti-)inflammatory components, astringent components, antihistamine components, anti-allergic components, collagen degradation inhibition components, liver protection (avoid or reduce liver toxicity) components, blood-retinal barrier enhancement components (making it more difficult for compounds to penetrate through the physiological barrier), amino acids, Antibacterial components, antioxidant components, sugars, polymers or their derivatives, cellulose or its derivatives, local anesthetic components, amblyopia treatment components, glaucoma treatment components, cataract treatment components, phosphodiesterase inhibitors (specific or non-specific), miRNA and its modifications, therapeutic components for ophthalmic diseases, ophthalmologically compatible excipients, liver extract, propolis, bilberry (orange) extract, anthocyanin, nano-selenium, vitamin E, vitamin C, vitamin B, lutein, astaxanthin, methandrosin, pyridoxine (such as pyridoxine hydrochloride), lipoic acid, etc. Of course, the medicine, preparation, composition or device of the present application may not contain any of the substances described in this paragraph.
[0036] In some embodiments, lipoic acid or lipoic acid choline ester, or its optical isomers or racemates, or its solvates, or its pharmaceutically acceptable salts or esters, or its prodrugs, or its metabolites, or its related compounds or extracts, or its crystalline compounds, or a combination of these substances and one or more drugs for delaying myopia progression and / or myopia treatment drugs are formulated or designed to be administered continuously, or simultaneously, or sequentially, or alternately, or intermittently, or separately.
[0037] In some embodiments, lipoic acid-related compounds include but are not limited to: salts further formed from lipoic acid esters, such as all salt forms of lipoic acid choline ester in CN115279745A, including but not limited to lipoic acid choline ester tosylate, lipoic acid choline ester benzenesulfonate, lipoic acid choline ester chloride or lipoic acid choline ester iodide; or the conjugates of these substances are the compounds in Figure 3 (Walter H. Moos et al., Epigenetic Treatment of Neurodegenerative Ophthalmic Disorders: An Eye Toward the Future., Biores Open Access., 2017 Dec 1; 6(1): 169-181.).
[0038] In some embodiments, lipoic acid and its related compounds include but are not limited to R (dextrorotatory) -lipoic acid, S (levorotatory) -lipoic acid (preferably R-α-lipoic acid), β-lipoic acid, dihydrolipoic acid, halogenated or deuterated lipoic acid and dihydrolipoic acid, lipoic acid structural analogs such as CMX-2043, ester forms or derivatives or structural analogs of lipoic acid such as PMX500FI, various salts of lipoic acid (such as sodium salt, lysine salt) or esters (especially lipoic acid choline ester, such as EV06) or alpha-LACE or UNR844) or amides (such as Lipoamide), lipoic acid choline ester toluenesulfonate, lipoic acid choline ester 3,-dihydroxybenzoate, lipoic acid choline ester benzenesulfonate, lipoic acid choline ester iodide or lipoic acid choline ester chloride, lipoic acid choline ester derivatives, other nanomaterials or biomacromolecules or chemical drugs modified with lipoic acid, lipoic acid prodrugs (such as lipoic acid choline ester or lipoic acid choline ester chloride), lipoic acid metabolites such as 6,8-bis(methylthio)octanoic acid (BMOA), 4,6-bis(methylthio)hexanoic acid (BMHA), 2,4-bis(methylthio)butanoic acid (BMBA), bisnorlipoic acid (BNLA), tetranorlipoic acid (TNLA), β-hydroxybisnorlipoic acid, etc.
[0039] In some embodiments, the derivative of thioctic acid choline ester can be understood as any compound or the mixture of compounds except thioctic acid and choline formed by reacting thioctic acid choline ester and non-aqueous pharmaceutical excipients. In certain embodiments, the derivative is the product formed by reacting thioctic acid choline ester and propylene glycol. In certain embodiments, the derivative is the product formed by reacting thioctic acid choline ester and glycerol.
[0040] In some embodiments, the metabolites of lipoic acid or its pharmaceutically acceptable salts or esters are 6,8-bis(methylthio)octanoic acid (BMOA) (6,8-bis(methylthio)octanoic acid), 4,6-bis(methylthio)hexanoic acid (BMHA) (4,6-bis(methylthio)hexanoic acid), 2,4-bis(methylthio)butanoic acid (BMBA) (2,4-bis(methylthio)butanoic acid), bis(methylthio)lipoic acid (BNLA) (bisnorlipoic acid), tetra(tetranorlipoic acid), β-hydroxybenzoic acid (β-hydroxybisnorlipoic acid), tetra(tetranorlipoic acid), and dimethylbis(methyl)lipoic acid.
[0041] In one embodiment, the various pharmaceutically acceptable salts or esters of lipoic acid of the present application are compounds described in CN115279745A or CN113387923A, especially the compounds described in claims 1-21 of CN113387923A. These compounds are believed to retain the basic functions of lipoic acid. For example, the present application provides a lipoic acid choline ester tosylate salt having the following structure:
[0042] In some embodiments, the present application provides a (R) lipoic acid cholinester tosylate salt having the following structure:
[0043] There is an enantiomeric excess of the R isomer of at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%.
[0044] In one embodiment, the present application provides a lipoic acid choline ester benzenesulfonate having the following structure:
[0045] In some embodiments, the present application provides a (R) lipoic acid cholinester benzenesulfonate having the following structure:
[0046] There is an enantiomeric excess of the R isomer of at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%.
[0047] In one embodiment, the present application provides a lipoic acid choline ester 3,4-dihydroxybenzoate having the following structure:
[0048] In some embodiments, the present application provides a (R) lipoic acid choline ester 3,4-dihydroxybenzoate having the following structure:
[0049] There is an enantiomeric excess of the R isomer of at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%.
[0050] In one embodiment, the lipoic acid-related compounds of the present application are compounds described in CN111315369A, especially the compounds described in claims 1-3 thereof, which are believed to retain the basic functions of lipoic acid. For example, compounds of formula I, or pharmaceutically acceptable hydrates, solvates, crystals, cocrystals, enantiomers, stereoisomers, polymorphs, or prodrugs thereof:
[0051] Among them, X + express,
[0052] In some embodiments, the compound is of Formula Ia, or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph, or prodrug thereof:
[0053] where X + As defined above.
[0054] In some embodiments, the compound is of Formula Ib, or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph, or prodrug thereof:
[0055] where X + As defined above.
[0056] In some embodiments, the drug, formulation or composition containing lipoic acid choline ester has counterions including but not limited to chloride, bromide, iodide, sulfate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, hydrogen fumarate, tartrate (optical isomers or mixtures thereof), succinate, benzoate and anions of glutamate, for example, WO 2018 / 055572 describes pharmaceutical compositions of LACE chloride and LACE iodide.
[0057] In some embodiments, lipoic acid choline ester is a prodrug of lipoic acid, which is hydrolyzed and becomes lipoic acid after application to the eye. In certain embodiments, the lipoic acid choline ester can also be considered a derivative of lipoic acid.
[0058] In some embodiments, dihydrolipoic acid is a metabolite of lipoic acid, and lipoic acid can be further reduced to produce dihydrolipoic acid in the eye.
[0059] Lipoic acid and its related compounds can also be produced by organisms. Therefore, the components or media for administering the drug in the treatment of myopia also include microorganisms or mammalian cells that can produce or secrete lipoic acid. Preferably, the microorganisms or mammalian cells are gene-edited or gene-modified.
[0060] In fact, the aforementioned lipoic acid-related compounds are all prior art and have been shown to have the same basic effects as lipoic acid, differing in solubility, corneal penetration, bioavailability, stability, etc. Those skilled in the art are also capable of preparing more other lipoic acid-related compounds that have the functions of lipoic acid.
[0061] In some embodiments, the preparation is an oral product such as a health product, food, dietary supplement, nutritional product, beverage, or cosmetic. The cosmetic can be a regular solution, aqueous solution, unsaturated solution, oil-water mixture, suspension (agent), liniment, lotion, spray, cream, drops, granule, ointment, paste, pill, suppository, emulsion, patch, or a combination thereof.
[0062] In some embodiments, the device is an instrument, equipment, consumables, system, medical device, health care product, or product that changes the appearance of the eye that can release drugs or has drug delivery function or potential drug delivery capability, such as corneal contact lenses, glasses, artificial lenses, sutures, OK lens cleaning (maintenance) systems, eye patches, eye patches, cosmetic contact lenses, microneedles, eye spray systems, eye massagers, eye fumigators, ocular surface drug delivery devices, intraocular drug delivery devices, fundus drug delivery devices, implantable pumps, wearable devices, acupoint massagers, eye relaxation devices, myopia treatment devices, or drug-device combinations for myopia prevention and control.
[0063] In some embodiments, lipoic acid or lipoic acid choline ester, or its optical isomer or racemate, or its solvate, or its pharmaceutically acceptable salt or ester, or its prodrug, or its metabolite, or its related compound or extract, or its crystalline compound, or a combination of these substances, is used as the sole active ingredient or the main active ingredient or the direct active ingredient; or: the content or efficacy of lipoic acid or lipoic acid choline ester, or its optical isomer or racemate, or its solvate, or its pharmaceutically acceptable salt or ester, or its prodrug, or its metabolite, or its related compound or extract, or its crystalline compound, or a combination of these substances accounts for 1% or less of the total active ingredients of the use (for example, containing The content or efficacy of lipoic acid or lipoic acid choline ester, or its optical isomer or racemate, or its solvate, or its pharmaceutically acceptable salt or ester, or its prodrug, or its metabolite, or its related compound or extract, or its crystalline compound, or a combination of these substances accounts for more than 20% (excluding 20%) of all raw material components for the use; the percentage (%) can be a mass ratio, a molar ratio, a potency ratio, or a contribution rate to the efficacy of the use.
[0064] In some embodiments, the concentration of lipoic acid or lipoic acid choline ester, or its optical isomer or racemate, or its solvate, or its pharmaceutically acceptable salt or ester, or its prodrug, or its metabolite, or its related compound or extract, or its crystalline compound, or a combination of these substances in the drug, formulation, composition or device is 0.001 μM to 10 mM, preferably 0.01 μM to 1000 μM, preferably 0.05 μM to 100 μM, more preferably 0.1 μM to 25 μM, more preferably 0.1 μM to 15 μM; 0.001 μM to 100 M, preferably 0.005 μM to 50 M, preferably 1 μM to 1 M, preferably 300 μM to 300 mM, more preferably 1 mM to 200 mM, more preferably 10 mM to 100 mM (such as about 46 mM, i.e. 0.94%); and / or: lipoic acid or lipoic acid choline ester, or its optical isomer or racemate, or its solvate, or its pharmaceutically acceptable salt or ester, or its prodrug, or its metabolite, or its related compound or extract, or its crystalline compound, or a combination of these substances in the drug, preparation, composition or device, the concentration or proportion of which is less than 25%, preferably less than 5%, preferably less than 1%, more preferably less than 0.01%, more preferably less than 0.001%; or greater than 0.0005%, preferably greater than 0.025%, preferably greater than 0.05%, more preferably greater than 0.1%, more preferably greater than 1%; or not less than 0.0001%, preferably not less than 0.001%, preferably not less than 0.01%, more preferably not less than 0.1%, more preferably not less than 0.8%, and the percentage (%) may be a mass / volume concentration (g per 100 ml) or a mass percentage or a molar (number) ratio.
[0065] The present application provides a drug, preparation, composition or device for ocular administration.
[0066] The present application also provides a pharmaceutical composition or compound preparation containing at least two active substances, including lipoic acid or lipoic acid choline ester, or its optical isomer or racemate, or its solvate, or its pharmaceutically acceptable salt or ester, or its prodrug, or its metabolite, or its related compound or extract, or its crystalline compound, or a combination of these substances and other active substances for treating myopia. Preferably, the amount, concentration and / or efficacy of lipoic acid or lipoic acid choline ester, or its optical isomer or racemate, or its solvate, or its pharmaceutically acceptable salt or ester, or its prodrug, or its metabolite, or its related compound or extract, or its crystalline compound, or a combination of these substances is not less than any other active substance for treating myopia, and the efficacy is for treating myopia or controlling myopia progression.
[0067] The present application also provides a pharmaceutical composition or compound preparation, including lipoic acid or lipoic acid choline ester, or its optical isomer or racemate, or its solvate, or its pharmaceutically acceptable salt or ester, or its prodrug, or its metabolite, or its related compound or extract, or its crystalline compound, or a combination of these substances and other active substances for treating myopia, wherein the other active substances for treating myopia include or do not include propolis, bilberry extract, anthocyanin, β-carotene, selenium or nano-selenium, vitamin E, vitamin C, lutein, taurine, astaxanthin, DHEA, grape seed extract, methandrosin, pyridoxine (such as pyridoxine hydrochloride) and the like. In some embodiments, the proportion or concentration of lipoic acid or lipoic acid choline ester in the pharmaceutical composition or compound preparation is at least 0.5%, 0.15%, 0.05%, 0.005% or 0.00001%.
[0068] The present application further provides an ophthalmic preparation or medicine, in which lipoic acid or lipoic acid choline ester, or its optical isomers or racemates, or its solvates, or its pharmaceutically acceptable salts or esters, or its prodrugs, or its metabolites, or its related compounds or extracts, or its crystalline compounds, or a combination of these substances serves as the direct, sole, or main active ingredient.
[0069] In some embodiments, the preparation or drug includes but is not limited to eye drops, eye ointments, eye sprays, implants, eye gels, eye patches, eye microspheres, eye sustained-release preparations, periocular injections, or intraocular injections.
[0070] In some embodiments, lipoic acid or lipoic acid choline ester, or its optical isomers or racemates, or its solvates, or its pharmaceutically acceptable salts or esters, or its prodrugs, or its metabolites, or its related compounds or extracts, or its crystalline compounds, or a combination of two or more of these substances are administered concurrently, such as simultaneously or sequentially in a specific medication (treatment) process, administered on the same day, administered in the same week, administered in the same month, or administered in the same year; or administered alternately at intervals, such as alternating administration at intervals of 4 hours, alternating administration at intervals of 12 hours, alternating administration every other day, alternating administration every other week, alternating administration every other month, or alternating administration every other year; or:
[0071] Lipoic acid or lipoic acid cholinester, or its optical isomers or racemates, or its solvates, or its pharmaceutically acceptable salts or esters, or its prodrugs, or its metabolites, or its related compounds or extracts, or its crystalline compounds, or a combination of these substances is administered concurrently with one or more other drugs, such as simultaneous or sequential administration, administration on the same day, administration in the same week, administration in the same month, or administration in the same year during a specific medication (treatment) process; or administration is alternately administered at intervals, such as alternating administration at intervals of 4 hours, alternating administration at intervals of 12 hours, alternating administration every other day, alternating administration every other week, alternating administration every other month, or alternating administration every other year; or:
[0072] Lipoic acid or lipoic acid choline ester, or its optical isomers or racemates, or its solvates, or its pharmaceutically acceptable salts or esters, or its prodrugs, or its metabolites, or its related compounds or extracts, or its crystalline compounds, or a combination of these substances is used in combination with a device (such as a corneal contact lens) and / or surgery (such as refractive surgery, myopic keratitis laser surgery, lens surgery).
[0073] In some embodiments, the ophthalmic dosage form containing lipoic acid as the main or only active ingredient is administered at a higher concentration or at a higher dosing frequency than an ophthalmic dosage form containing lipoic acid cholinester as the main or only active ingredient.
[0074] In some embodiments, the one or more other drugs are myopia prevention and control and / or myopia treatment drugs, such as atropine sulfate, dimethoprim, polyunsaturated fatty acids, DHA, fish oil, M receptor blockers, niacin, pirenzepine, muscarinic antagonists, 7-methylxanthine (7MX), ampicillin, indolepiperamide, timolol maleate, epinephrine, pyrazine, pirenzepine, pyrenzepine, methylamine, closporin, acetylcholinesterase inhibitors, dopamine agonists, γ-aminobutyric acid, naloxone, pancreatic hyperglycemia, etc. Glucose, retinoic acid, salidroside, formononetin, etc., vasodilators, smooth muscle relaxants, drugs to prevent vasospasm, drugs to regulate collagen metabolism, piracetam, anti-allergic drugs, liver-protecting drugs, drugs to relieve gastrointestinal irritation, propolis, bilberry extract, anthocyanidins, β-carotene, selenium or nano-selenium, vitamin E, vitamin C, lutein, taurine, astaxanthin, DHEA, grape seed extract, methandrosin, pyridoxine (such as pyridoxine hydrochloride), etc. Of course, the drugs, preparations, compositions or devices of the present application may not contain any one or more of the substances described in this paragraph.
[0075] In some embodiments, the device is various glasses that delay the progression of myopia, OK glasses, frame glasses, eye patches, (myopia) acupoint massagers, eye relaxation equipment, myopia treatment devices, etc., which have the function of protecting vision or treating (correcting) myopia, equipment, consumables, medical devices or health care products.
[0076] In some embodiments, in achieving the use, a systemic dosage form (such as oral tablets) and a local dosage form (such as eye drops) are used simultaneously, in combination, alternately, intermittently, or separately.
[0077] In some embodiments, the abnormal development of the eye is primarily genetic, including information encoded in DNA and / or epigenetic characteristics.
[0078] In some embodiments, the abnormal development of the eye is refractive developmental abnormality induced mainly by environmental factors or mainly caused by human factors (such as prolonged close reading, frequent use of electronic screens, continuous near vision without the opportunity for hyperopia, improper use of refractive correction glasses, side effects of drugs, obesity, trauma, poor lighting in the learning environment, lack of outdoor exercise), and is not related to genetic factors, or genetic factors are secondary factors, accompanying factors, or synergistic factors. The abnormal development is, for example, abnormal development of the eyeball size in children and adolescents (such as 2-30 years old).
[0079] In some embodiments, abnormal development or developmental abnormality includes excessive axial length or a mismatch between the rate of axial lengthening and the refractive system, resulting in parallel light rays passing through the normal or abnormal refractive system of the eye with the focus of imaging located in front of the retina. BRIEF DESCRIPTION OF THE DRAWINGS
[0080] Figure 1: Lipoic acid controls myopia progression. Comparison of differences in refraction, vitreous cavity depth, and axial length between the two eyes of the lipoic acid-treated group and the negative control group before, one week after, and two weeks after the experiment. A: The difference in refraction between the experimental and fellow eyes; B: The difference in axial length between the experimental and fellow eyes; C: The difference in vitreous cavity depth between the experimental and fellow eyes. * indicates p < 0.05, ** indicates p < 0.01, and *** indicates p < 0.001. Refraction: refraction; VCD: vitreous cavity depth; AL: axial length; n: sample size; Vehicle: vehicle; lipoic acid: lipoic acid.
[0081] Figure 2: Effects of lipoic acid on anterior chamber depth (A), lens thickness (B), corneal curvature (C), and pupil diameter (D). ACD: anterior chamber depth; LT: lens thickness; RCC: corneal curvature; PD: pupil diameter; n: sample size; Vehicle: vehicle; lipoic acid: lipoic acid.
[0082] Figure 3: Examples of lipoic acid and related compounds.
[0083] Figure 4: Effects of lipoic acid, methandrol, pyridoxine, astaxanthin, and bilberry extract on the refractive index of myopic individuals. Comparison of the difference in refractive index between the eyes of the same subject before, after one week, and after two weeks of treatment. n: sample size. w: week. *P < 0.05, **P < 0.01, ***P < 0.001.
[0084] Figure 5: Effects of lipoic acid, metformin, pyridoxine, astaxanthin, and bilberry extract on vitreous cavity depth and axial length in myopic individuals. Comparison of the differences in axial length (A) and vitreous cavity depth (B) between the eyes of the same subject before, after one week, and after two weeks of treatment. VCD: vitreous cavity depth. AL: axial length. n: sample size. w: weeks. *P < 0.05, **P < 0.01, ***P < 0.001.
[0085] Figure 6: Effects of atropine, lipoic acid, metformin, pyridoxine, astaxanthin and bilberry extract on pupil size in test animals.
[0086] Figure 7: Effects of lipoic acid as the primary or direct active ingredient on the progression of negative refractive power and axial length elongation in myopic individuals. Comparison of differences in refractive power (A) and axial length (B) between the eyes of the same subject before, after one week, and after two weeks of administration of different formulation ratios of the pharmaceutical composition. P value = 0.0569 for control vs. BFE (0.05%) + DL-ALA (1%) at 2 weeks of FD. n: Sample size. w: Weeks. *P < 0.05, **P < 0.01.
[0087] Figure 8-1: Lipoic acid choline ester eye drops significantly treat myopia. Comparison of the difference in refractive power (A) between the same subjects before, after, and after one and two weeks of lipoic acid choline ester eye drops at different concentrations. Comparison of the difference in axial length (B) between the same subjects before and after two weeks of lipoic acid choline ester eye drops at different concentrations. n: Sample size. w: Weeks. *P < 0.05, **P < 0.01, ***P < 0.001.
[0088] Figure 8-2: Effects of different concentrations of lipoic acid choline ester on corneal curvature (A), anterior chamber depth (B), and lens thickness (C). ACD: anterior chamber depth; LT: lens thickness; RCC: corneal curvature; n: sample size.
[0089] Figure 9: Both lipoic acid optical isomers and dihydrolipoic acid are effective in treating the minus-mirror-induced myopia model. Comparison of the difference in refractive power between the eyes of the same subject before, 3 days after, and 7 days after administration of different chiral lipoic acids or their metabolites. n: Sample size. d: Day. *P < 0.05, **P < 0.01.
[0090] Figure 10: Effects of lipoic acid optical isomers and dihydrolipoic acid on lens thickness (A) and anterior chamber depth (B) of the LIM model.
[0091] Figure 11: The effect of a pharmaceutical composition containing lipoic acid on the progression of negative refraction and axial length in myopic individuals. The difference in refraction (A) and axial length (B) between the eyes of the same individual was evaluated before, one week after, and two weeks after administration of a low-concentration atropine-lipoic acid combination. n: Sample size. w: Weeks. *P < 0.05, **P < 0.01, ***P < 0.001.
[0092] Figure 1 2: Lipoic acid choline ester can effectively increase choroidal thickness in myopic individuals when administered as eye drops. ChT: choroidal thickness, n: sample size.
[0093] Figure 13: Both lipoic acid optical isomers and dihydrolipoic acid can effectively increase choroidal thickness in myopic individuals. ChT: choroidal thickness, n: sample size, *P < 0.05. DETAILED DESCRIPTION
[0094] The following examples of the present application are illustratively presented. Although the present application has been described in conjunction with these specific embodiments, it should be understood that it is not intended to limit the present application to such specific embodiments. On the contrary, the present application is intended to cover alternatives, modifications, substitutions, variations and equivalents that may be included in the spirit and scope of the present application as defined by the appended claims.
[0095] The present application provides a method for preventing and treating myopia, which involves administering lipoic acid or lipoic acid choline ester, or its optical isomers or racemates, or its solvates, or its pharmaceutically acceptable salts or esters, or its prodrugs, or its metabolites, or its related compounds or extracts, or its crystalline compounds, or a combination of these substances.
[0096] The present application further provides myopia treatment and control myopia progression medicine for topical application in the eye, using lipoic acid or lipoic acid choline ester as the only, or main, or direct active ingredient. In the prior art, lipoic acid is mainly tablets, capsules and injections, and is systemically administered. And when lipoic acid or lipoic acid choline ester is used to treat myopia, if systemic administration is performed, it will be affected by the first-pass effect of the drug, blood-retinal barrier (blood-retinal barrier, BRB), etc., and it is necessary to give a large dose of medicine to ensure that the lipoic acid or its metabolites entering the eye reach the therapeutic concentration threshold. Such a treatment strategy has the potential risk of systemic adverse reactions, especially the object is a low-age population and requires long-term continuous administration. At the same time, systemic administration is affected by more individual differences, which increases the uncertainty of the myopia control efficacy of lipoic acid or lipoic acid choline ester. Therefore, the present application has developed a lipoic acid medicine with better effectiveness and safety, applied topically in the eye. This drug development strategy targets the use of lipoic acid and its related compounds (such as UNR844 Chloride) in the prevention and control of myopia in children and adolescents. The advantages are that patients can use the medication conveniently and have high compliance. The medication can be given for a long time (such as one month, six months, one year, three years, five years, or ten years). The growth and development of young individuals are less affected, and the ophthalmic dosage form is safe and reliable.
[0097] The present application also provides a method, which comprises administering to a suitable subject an effective dose of lipoic acid or lipoic acid choline ester, or its optical isomers or racemates, or its solvates, or its pharmaceutically acceptable salts or esters, or its prodrugs, or its metabolites, or its related compounds or extracts, or its crystalline compounds, or a combination of these substances.
[0098] The method or pharmaceutical composition of the present application can significantly inhibit the occurrence and development of myopia, and can significantly inhibit and slow down the elongation of the axial length and / or the increase in vitreous cavity length in myopic individuals (including individuals who are not yet myopic but are about to develop myopia), and can increase the choroidal thickness of such people. Preferably, the method or pharmaceutical composition of the present application is applicable to a population including those suffering from childhood and / or adolescent myopia (preferably a population aged 2-30 years, more preferably a population aged 6-18 years), or early or mid-term myopia, or mild or moderate myopia, or non-pathological myopia, or axial simple myopia, or childhood and / or adolescent axial myopia (preferably a population aged 2-30 years, more preferably a population aged 6-18 years), or childhood and / or adolescent progressive myopia (preferably a population aged 2-30 years, more preferably a population aged 6-18 years), or primary myopia, or non-senile myopia, or juvenile myopia, or progressive myopia, or non-refractive myopia. The axial length elongation and / or increase in vitreous cavity length of these myopic individuals (including individuals who are not yet myopic but are about to develop myopia) are inhibited or even stopped by the method, preparation or pharmaceutical composition of the present application.
[0099] The present application provides a method for treating, preventing or alleviating myopia and related symptoms in a subject, comprising administering to the subject a therapeutically effective amount of lipoic acid or lipoic acid choline ester, or an optical isomer or racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt or ester thereof, or a prodrug thereof, or a metabolite thereof, or a related compound or extract thereof, or a crystalline compound thereof, or a combination of these substances. Preferably, lipoic acid or lipoic acid choline ester, or its optical isomer or racemate, or its solvate, or its pharmaceutically acceptable salt or ester, or its prodrug, or its metabolite, or its related compound or extract, or its crystalline compound, or a combination of these substances is administered alone; preferably, lipoic acid or lipoic acid choline ester, or its optical isomer or racemate, or its solvate, or its pharmaceutically acceptable salt or ester, or its prodrug, or its metabolite, or its related compound or extract, or its crystalline compound, or a combination of these substances is administered in the form of a pharmaceutical composition; preferably, the pharmaceutical composition is prepared as an ophthalmic preparation; preferably, the ophthalmic preparation further comprises a pharmaceutically acceptable carrier; preferably, the carrier is an ophthalmologically acceptable carrier.
[0100] The present application also provides a pharmaceutical composition for treating, preventing or slowing down myopia and its related symptoms, the pharmaceutical composition thioctic acid or thioctic acid choline ester, or its optical isomer or its racemate, or its solvate, or its pharmaceutically acceptable salt or ester, or its prodrug, or its metabolite, or its related compound or extract, or its crystalline compound, or a combination of these substances. The present application also provides thioctic acid or thioctic acid choline ester, or its optical isomer or its racemate, or its solvate, or its pharmaceutically acceptable salt or ester, or its prodrug, or its metabolite, or its related compound or extract, or its crystalline compound, or a combination of these substances in the preparation of a pharmaceutical composition for treating, preventing or slowing down myopia and its related symptoms. Preferably, the pharmaceutical composition is prepared into an ophthalmic preparation, preferably, the ophthalmic preparation also includes a pharmaceutically acceptable carrier, preferably, the carrier is an ophthalmologically acceptable carrier, preferably, the carrier is an ophthalmologically compatible carrier.
[0101] The present application also provides a myopia treatment (inhibiting myopia progression) scheme in which lipoic acid or lipoic acid choline ester, or its optical isomers or racemates, or its solvates, or its pharmaceutically acceptable salts or esters, or its prodrugs, or its metabolites, or its related compounds or extracts, or its crystalline compounds, or a combination of these substances is used in combination with, or intermittently or alternately with, other myopia prevention and control drugs (such as atropine) or optical prevention and control measures (such as OK glasses, various forms of optical therapeutic devices) or refractive surgery in the prevention, alleviation and treatment of myopia.
[0102] The present application also provides lipoic acid or lipoic acid choline ester, or its optical isomers or racemates, or its solvates, or its pharmaceutically acceptable salts or esters, or its prodrugs, or its metabolites, or its related compounds or extracts, or its crystalline compounds, or a combination of these substances, in the prevention, alleviation and treatment of myopia, a myopia treatment (inhibition of myopia progression and / or axial elongation) regimen using its systemic dosage form (such as oral tablets) and local dosage form (such as eye drops) in combination or alternating use.
[0103] Terms and Definitions
[0104] "Myopia" refers to the situation in which parallel light rays converge in front of the retina after passing through the eye's refractive system in a relaxed state of accommodation. Myopia is usually manifested by lower-than-normal distance vision and normal near vision. The clinical concept of a myopic individual is: a person with a static refraction of ≥-0.25D. The clinical manifestations are blurred vision at a distance and good vision at a close distance. In the early stages of myopia, there are often fluctuations in distance vision. Since no or little accommodation is used when looking at close objects, the convergence function is correspondingly weakened, which can easily cause exophoria or exotropia. In some paragraphs of this article, the concepts represented by the words "myopia" and "myopia" are the same, and the two can be used interchangeably. Researchers in this field should correctly understand the meaning of "myopia" or "myopia" in this patent based on the context in which they are used.
[0105] First, there are four common types of myopia: (1) Based on the size of the refractive power, it can be divided into mild (300 degrees and below), moderate (300 degrees to 600 degrees) and severe (600 degrees or above -6D); (2) Based on whether the refractive component is abnormal, it can be divided into refractive myopia and axial myopia; (3) Based on whether pathological changes occur, it can be divided into pathological myopia and simple myopia; (4) Based on the cause, it can be divided into primary myopia and concurrent / secondary myopia.
[0106] In some embodiments, myopia or myopia complications may include or exclude any one or more of the myopia types or myopia complication types mentioned in this application, such as:
[0107] "Mild or moderate myopia" means that the patient has no other symptoms except blurred vision of distant objects. That is, the main symptoms are a gradual decrease in distance vision, blurred vision of distant objects, and normal near vision. Usually, there are no special changes in the eyes except for the length of the eye axis.
[0108] High myopia (e.g., -6D) is characterized by a deep anterior chamber, a large pupil, and a slightly protruding eyeball due to its excessively long anterior-posterior axis. A white or grayish-white crescent-shaped spot, called a myopic lunula, can be seen temporally on the optic disc. This is caused by posterior elongation of the sclera, which causes the retinal pigment epithelium and choroid to separate from the temporal edge of the optic disc, exposing the sclera or parts of the choroid and sclera. Continued posterior expansion of the sclera can cause genu-shaped streaks and subretinal neovascularization in the macula, with patchy atrophy and degeneration of the adjacent retina and choroid, leading to a posterior scleral staphyloma. The macula often exhibits pigment hyperplasia and even hemorrhage, forming a Forster-Fuchs spot. Such patients often experience vitreous liquefaction and opacification, and a few may develop retinal detachment and cataracts. Furthermore, high myopia often results in poor vision at both near and far distances due to opacities in the refractive media and degeneration of the retina and choroid, sometimes accompanied by the appearance of dark shadows before the eyes. If such a lesion occurs, this type of myopia is no longer simple myopia.
[0109] "Refractive myopia" is mainly caused by excessive curvature of the cornea or lens, which causes the refractive power to exceed the normal range, while the axial length of the eye is within the normal range.
[0110] Axial myopia is a condition in which the axial length of the eye exceeds the normal range, while the curvature of the cornea and lens are generally within the normal range. Axial myopia is the main type of myopia in children and adolescents.
[0111] "Pathological myopia", also known as degenerative myopia or malignant myopia, is a degenerative lesion of the fundus. Patients with myopia usually have a high refractive power (such as greater than 600 degrees), their visual function is significantly impaired, and their distance vision is even worse. In addition, abnormalities are often seen in their visual field, light perception, and contrast perception, often accompanied by poor night vision (night blindness), floaters, floaters, and flashes of light. Thinning of the retinal pigment epithelium and choroid can be seen in the fundus of patients, often accompanied by symptoms such as retinal pigment epithelium atrophy, choroidal neovascularization, retinal detachment, and macular degeneration. In addition, pathological changes in the fundus continue to develop after development stops. This type of myopia can be severe and can cause blindness.
[0112] "Simple myopia" refers to myopia that develops during the eye's growth period. Once growth stops and the refractive power stabilizes, it often develops during school age, with a myopia degree below 600 degrees and no obvious pathological changes in the fundus. This is also called acquired myopia. This type of myopia progresses, with a gradual increase in axial length. Vision can be corrected to normal with appropriate lenses, and other visual function indicators are generally normal. The opposite is considered non-simple myopia, and examples of non-simple myopia include pathological myopia, high myopia, senile myopia, and complex myopia.
[0113] "Primary myopia" is the main type of myopia. "Primary" refers to a type of myopia with unknown etiology and pathogenesis, for which current diagnostic techniques have yet to determine. During its development, it manifests as pathological or physiological functional-structural changes specific to myopia, including congenital myopia and acquired simple myopia.
[0114] "Concurrent / secondary myopia" refers to temporary or accompanying myopia caused by eye accommodation dysfunction or abnormal refractive index due to internal and external factors, such as toxic myopia, drug-induced myopia, traumatic myopia, diabetic myopia and initial cataract myopia, myopia caused by diabetes, myopia caused by oxidative degeneration of the lens, myopia caused by corneal damage or oxidative degeneration, progressive complex myopia accompanied by lipid peroxide oxidation (POL) disorder, etc. This type of myopia is characterized by clear inducing factors. When medical means are used to intervene in the inducing factors, the degree of myopia can be alleviated or reversed. Therefore, patients with this type of myopia have repeated fluctuations in vision. This type of myopia is also often prevalent among the elderly.
[0115] "Axial simple myopia", sometimes also called simple axial myopia, is a type of simple myopia characterized by simple myopia in which the image focus is located in front of the retina due to elongation of the eye axis and / or increased depth of the vitreous cavity. This type of myopia has a relatively normal refractive structure (such as the lens) and is the most common type of myopia in children and adolescents. It is more common in children aged 2 to 30 years, especially those aged 6 to 18 years (Paul N Baird, Nat Rev Dis Primers. 2020 Dec 17; 6(1): 99. and AJ Adams, Am J Optom Physiol Opt. 1987 Feb; 64(2): 150-2 and Seang-Mei Saw, Ophthalmic Physiol Opt. 2005 Sep; 25(5): 381-91.).
[0116] "Curvature myopia" is myopia caused simply by an increase in the curvature of the cornea or lens.
[0117] "Index myopia" is myopia caused by the increase in refractive power due to the increase in the refractive index of aqueous humor and lens, which belongs to refractive myopia.
[0118] "Progressive myopia" refers to a type of myopia in which the refractive power continues to decrease over time or as the individual ages. If this type of myopia is not intervened or the patient's age has not yet reached the point where eye growth and development stops, it will generally eventually develop into high myopia.
[0119] "Children's and adolescents' myopia" is a simple form of myopia caused by prolonged close-up use. The vast majority of patients with this condition do not develop pathological myopia. The eyes of children and adolescents are still in their growth and development stages, with strong accommodation capabilities and relatively high scleral elasticity. When engaged in close-up tasks such as reading and writing, the eyes are out of focus. Over time, the anterior-posterior axis of the eye becomes elongated, making axial myopia a common condition in children and adolescents. Without changes in eye habits or medical intervention, the severity of myopia in children and adolescents will gradually worsen, leading to further increases in axial length. Therefore, as children and adolescents grow and develop, and their academic pace is intense, the increase in axial length and the corresponding decrease in refractive power are dynamic, representing a progressive form of myopia, rather than the static state seen in adults and the elderly. Therefore, the efficacy of drugs used to treat this type of myopia is primarily evaluated based on controlling myopia progression and inhibiting axial elongation.
[0120] "Myopia in the elderly" is usually more complicated and easily affected by aging of body organs and underlying diseases. It is often accompanied by symptoms such as blood sugar changes, vascular sclerosis, insufficient blood supply, ocular microcirculation disorders, oxidative stress, and most of the patients receiving treatment clinically are highly myopic. A notable feature of adults or elderly myopic patients is that the degree of myopia generally does not increase with age. The main reason is that the eye growth and development of such individuals basically stops, and the axial length no longer changes due to long-term close viewing. Therefore, myopia in the elderly (including adults) and myopia in children and adolescents (minors) are two completely different types of diseases. It is necessary to clearly distinguish these two indications in the treatment of myopia. Although the medicine or method of the present application is suitable for treating various myopia types, it is preferred to use simple myopia, axial myopia and children and adolescent myopia, while excluding non-simple myopia such as elderly myopia, malignant myopia, and pathological myopia, because the clinical intervention strategy for these myopic patients is no longer to inhibit the extension of the axial length, but more to prevent blindness caused by serious eye lesions, such as blindness caused by retinal detachment.
[0121] "Myopia-related symptoms" include complications caused by myopia, such as complications of high myopia, such as floaters, glaucoma, posterior scleral staphyloma, retinal detachment, retinal tear, amblyopia, macular hemorrhage, choroidal neovascularization, choroidal atrophy, macular degeneration or macular degeneration, visual field defects, progressive or sudden decrease in vision (especially near vision), eye soreness and / or pain, poor night vision (such as night blindness), astigmatism, anisometropia, blindness, vitreous liquefaction, vitreous opacities, strabismus, frequent blinking, flashes of light, frequent rubbing of eyes, blurred vision when looking at distant objects, the need to squint or partially close the eyelids to see distant objects clearly, headaches caused by eyestrain, and difficulty seeing while driving, especially Night vision (night myopia), retinal atrophy and degeneration (hemorrhage and holes), subretinal neovascularization, and eyeball atrophy; fundus changes of varying degrees may also occur, myopic arcuate plates, macular hemorrhage or formation of subretinal neovascular tumors, irregularly shaped white atrophic spots, or circular black spots with pigmentation (Fuchs spots), lattice degeneration and cystic degeneration of the retina, vitreous liquefaction, turbidity and posterior vitreous detachment at a young age, the risk of retinal holes and detachment is higher than that of normal people, often due to the long anteroposterior diameter of the eyeball, the protruding eyeball, and the extreme expansion of the posterior eyeball, forming scleral staphyloma; choroidal atrophy, retinal lesions, macular hemorrhage, etc. caused by myopia, especially high myopia.
[0122] "Complex myopia": also known as complex myopia. Compared with simple myopia, the main clinical manifestation of complex myopia is that complications caused by myopia, especially high myopia, endanger vision (whether near vision or distance vision) or cause serious vision impairment (such as retinal detachment, blindness, etc.), rather than just a simple decrease in refractive power in myopia. Complex myopia is common in progressive complex myopia accompanied by lipid peroxide oxidation POL disorder, myopia in the elderly, myopia caused by high blood sugar (such as diabetic myopia), or high myopia. On the contrary, it is non-complex myopia. Examples of non-complex myopia include childhood and adolescent myopia, axial myopia, simple myopia, progressive myopia, mild myopia and moderate myopia.
[0123] "Accommodative tension myopia" is caused by excessive near vision load on the eyeball and excessive adjustment of the ciliary muscle, resulting in myopia caused by accommodation tension or accommodation spasm.
[0124] "Astigmatic myopia" is a type of myopia in which the external light is scattered in all directions and cannot form a focus on the retina due to damage to the cornea or different degrees of curvature.
[0125] "Pseudomyopia" refers to the disappearance of myopia and the appearance of emmetropia or hyperopia when checking the refractive power after using ciliary muscle paralyzers.
[0126] "True myopia" refers to the common myopia, which means that the myopia refractive power does not decrease after using ciliary muscle paralyzers, or the reduction is less than 0.5D.
[0127] "Mixed myopia" refers to the condition in which the myopia refractive power is significantly reduced after using ciliary muscle paralytics, but it does not return to emmetropia.
[0128] Other types of myopia include traumatic myopia, toxic myopia, drug-induced myopia, diabetic myopia, instrumental myopia, spatial myopia, night myopia, other premature infant myopia, diving myopia, hysterical myopia, and temporary myopia that occurs during menstruation, pregnancy, and various eye and systemic diseases. Among them, "traumatic myopia" refers to blunt trauma to the eye, which can induce myopia, and the refractive power is often less than -6.00D.
[0129] "Toxic myopia" is a myopic reaction caused by acute or chronic poisoning by toxic substances such as organophosphorus pesticides.
[0130] "Drug-induced myopia" refers to myopia induced by various drugs, such as sulfonamides, diuretics, tetracycline, adrenocorticotropic hormone and contraceptives.
[0131] "Diabetic myopia" is a temporary myopia that occurs in diabetics.
[0132] "Instrumental myopia" is myopia caused by long-term close-range operation of instruments or equipment.
[0133] "Spatial myopia" is a myopia phenomenon caused by the lack of visual stimulation in a normal environment when a person is at a high altitude and looking at the empty space around him.
[0134] "Night myopia" is a myopia condition that occurs when the human eye is in a dark environment with dim light.
[0135] Secondly, the intervention measures for myopia can be divided into myopia correction and myopia treatment, among which myopia treatment has the main feature and purpose of inhibiting (controlling) the progression of myopia.
[0136] "Myopia correction" is to correct or reduce the degree of myopia through optical methods. Commonly used correction methods include wearing frame glasses, clear lens phacoemulsification, intraocular lens implantation, corneal laser surgery, etc. However, this method only corrects the individual's refractive power and cannot delay the progression of myopia or reverse the excessive length of the eye axis. In other words, this type of myopia intervention method usually does not stop or slow down the process of continuous negative refractive power and cannot inhibit the progression of myopia. Therefore, myopia correction methods such as corneal laser surgery will compensate for the patient's refractive error and restore their distance vision. It is suitable for improving vision in people with pathological myopia, high myopia or elderly myopia, but it is not suitable for treating axial myopia or simple myopia, such as children or adolescents with myopia, primary myopia, or mild or moderate myopia. In fact, although the distance vision of individuals with axial myopia is temporarily restored after wearing frame glasses, this correction method will not inhibit the further elongation of their eye axis or control the speed of their myopia development. In the absence of other drug treatments, the result is that the degree of myopia will further increase, and patients will need to replace frame glasses with higher degrees every once in a while to continue to correct their vision.
[0137] "Inhibiting (controlling) the progression of myopia" refers to the use of various methods or drugs to delay (slow down) the continuous deepening of myopia, slow down the speed of negative refractive power, control the development of myopia and inhibit (control) the continuous elongation of the axial length. It is an etiological treatment, and the patients targeted are mostly minors who are still in the stage of eye development. For the treatment of myopia in children or adolescents, slowing down, controlling or even stopping the continuous negative refractive power and inhibiting the corresponding increase in axial length are the primary goals of the development of myopia treatment drugs. That is, the treatment of myopia for children or adolescents, axial myopia, simple myopia and other types of myopia should achieve the effect of controlling or inhibiting the development of myopia, rather than simply reversing or correcting this refractive error.
[0138] Unless otherwise specified, the "treatment (myopia)" of the present application refers to suppressing (controlling) myopia progression, rather than correcting myopia. The terms "treatment", "slowing down", "delaying", "suppression" or "control" used herein refer to treatment measures, with the purpose of slowing down (alleviating) or terminating target disease or disorder. For example, after receiving a lipoic acid compound or a pharmaceutical composition containing the therapeutic amount of the method described herein, the object shows one or more symptoms of ophthalmological disease and symptoms that can be observed and / or measured and are suppressed, delayed, reduced and disappear, or are the slowing down and delay of the progression of the disease, and the ophthalmological disease of the object is successfully treated.
[0139] It should also be understood that drugs that can treat myopia usually also have a "preventive" effect, that is, they can prevent the occurrence and development of myopia. Therefore, this article often uses "prevention and control" to express the meaning of treatment and prevention.
[0140] The various modes of treatment or prevention of medical conditions described herein are intended to represent "significant", which include complete treatment or prevention and less than complete treatment or prevention, wherein a certain biologically relevant or medically relevant result is achieved. In some embodiments, "treatment" does not require 100% elimination of myopia or myopia symptoms. In some embodiments, compared to the levels observed in the absence of the present application's compositions or methods (for example, in biologically matched control subjects or specimens not exposed to the compounds of the present application's compositions or methods), "treatment" of myopia or myopia-related symptoms according to the present application's methods has been achieved, such as prevention, alleviation, inhibition, and prevention of myopia progression of at least about 5%, at least about 10%, or at least about 20%. In some embodiments, compared to myopia or myopia-related symptoms in the absence of the compounds of the present application's methods, myopia or myopia-related symptoms are treated by at least about 30%, at least about 40%, at least about 50%, or at least about 60%, at least about 70%, at least about 80%, at least about 90% or more (about 100%). Therefore, those skilled in the art will understand that "treat", "slow down", "delay", "inhibit", "control" or "prevent and control" are direct effects, and do not refer to eye health effects or auxiliary therapeutic effects that are beneficial to myopia treatment in an indirect way, such as enhancing eye blood circulation, improving eye comfort during application, etc.
[0141] Third, the evaluation method for the effectiveness of myopia treatment (drug efficacy) involves many factors, such as whether the sample group was selected scientifically, whether objective controls were set up, and whether an effective dose was administered. Specifically, if the sample group is mostly elderly (whose eye development has stopped and who may have underlying diseases such as arteriosclerosis), it will be difficult to prove that the drug has a therapeutic effect on progressive myopia. If the efficacy of the drug is evaluated only through vision tests without any parallel control (such as a placebo group or the other eye), it will also be impossible to prove that the drug (such as lipoic acid) has a therapeutic effect on myopia. This application uses two classic myopia disease models, form deprivation and negative mirror-induced, in young animals whose eyes are still in the growth and development stage, which are commonly used in the preclinical development stage of actual myopia drugs, as well as scientific experimental standards in this field to evaluate the efficacy of compounds in preventing and controlling myopia, especially preventing and controlling myopia and / or simple myopia in children and adolescents (DA Goss, Am J Optom Physiol Opt. 1981 Oct; 58(10): 859-69. and Hao Wu, Proc Natl Acad Sci US A. 2018 Jul 24; 115(30): E7091-E7100. and Sen Zhang, Invest Ophthalmol Vis Sci. 2019 Jul 1; 60(8): 3074-3083.).
[0142] "Pharmacological efficacy" refers to the evaluation of the effect of a specific pharmaceutical composition or preparation on the treatment of myopia or the comparison of the efficacy of a specific pharmaceutical composition or preparation, using refractive index or a combination of refractive index and axial length parameter (length) as the judgment index in accordance with the requirements of the drug registration application and the relevant contents of the "Technical Guidelines for Clinical Research on Drugs for Controlling Myopia Progression" formulated by the China Drug Evaluation Center. At the same time, changes in corneal curvature, vitreous cavity depth, choroidal thickness, and axial length compared to the baseline can also be used as secondary efficacy indicators for evaluating myopia treatment. The evaluation method of pharmaceutical efficacy or the calculation method of pharmaceutical efficacy contribution rate can use, for example, the change in refractive index compared to the baseline, the change in axial length compared to the baseline, the change in vitreous cavity depth compared to the baseline, etc. The positive efficacy judgment standard can be a 50% reduction in the progression of refractive error compared to the control, or a difference in refractive index between groups exceeding 0.75D after 3 years of treatment. For myopia treatment drugs containing two or more active ingredients, scientifically and rationally designed single and compound preparations containing all active ingredients are evaluated for their efficacy in treating myopia. This can determine the efficacy contribution rate of each active ingredient and its role in the compound preparation (such as synergistic effect, stabilizer effect, absorption promotion effect, etc.). In terms of efficacy in preventing (controlling) myopia, inhibiting myopia progression, and correcting myopia, the above-mentioned myopia treatment evaluation indicators, judgment criteria, and active ingredient effect evaluation methods can also be used to determine or derive the efficacy of a specific compound (such as lipoic acid or lipoic acid choline ester) and its clinical significance.
[0143] Fourthly, other common terms are explained.
[0144] "Far vision" is also known as naked eye far vision. Medically, it refers to the vision measured when looking straight ahead with eyes open at a horizontal distance of 5 meters from the eye chart, without wearing glasses or any auxiliary equipment that can enhance vision (such as frame glasses, contact lenses, cosmetic contact lenses, pinhole lenses, etc.).
[0145] "Topical administration" refers to direct administration to the desired part of the body or a method of administration that can achieve local effect, including but not limited to: epidermal administration, inhalation administration, enema administration, ocular administration, and nasal administration.
[0146] "Systemic administration" is also called systemic administration, which includes intravenous administration, oral administration, intramuscular injection, subcutaneous injection and other administration methods. The drugs can be transported through the blood and distributed throughout the body.
[0147] "Improved systemic drug delivery" refers to a safe, efficient and convenient systemic drug delivery method that can utilize specific drug targeting technologies to effectively reduce the toxicity of systemically administered drugs while enriching lipoic acid drugs in the eye.
[0148] "Directly active ingredient" is also called "(drug) active ingredient (Active pharmaceutical ingredient)", which refers to a substance that has a direct therapeutic effect on a disease (such as myopia). It is a necessary condition for treating the disease or its parameters such as dosage and administration method directly affect the therapeutic effect of the disease. There is a clear causal relationship between the administration of the ingredient and the effect of treating the disease. For example, in a compound preparation, if the efficacy of the preparation after the ingredient is removed is worse than that of the original formula and there is a significant difference, then the removed ingredient is regarded as a directly active ingredient.
[0149] "Sole active ingredient" means that there is only one ingredient in the final product (such as a drug) that exerts a medicinal effect, such as directly inhibiting, preventing and / or treating myopia.
[0150] "Main active ingredient" refers to an active ingredient whose added amount, proportion, concentration or efficacy is not lower than other active ingredients in the final product (such as medicine) (such as the treatment of myopia); or its content accounts for more than 50%, more than 60%, more than 70%, more than 80%, or more than 90% of all active ingredients, and the percentages are mass ratios or molar ratios.
[0151] "These substances" refer to lipoic acid or lipoic acid choline ester, or optical isomers or racemates thereof, or solvates thereof, or pharmaceutically acceptable salts or esters thereof, or prodrugs thereof, or metabolites thereof, or related compounds or extracts thereof, or crystalline compounds thereof.
[0152] "Ophthalmologically compatible" refers to formulations, polymers and other materials and / or dosage forms that are suitable for use in contact with ocular tissues of humans and animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit / risk ratio.
[0153] In this specification and the appended claims, singular forms, including the singular forms "a," "an," and "the," also specifically encompass plural referents of the terms they refer to, unless the context clearly dictates otherwise. Additionally, as used herein, the word "or" is used in its "inclusive" sense of "and / or" rather than its "exclusive" sense of "either / or," unless specifically indicated otherwise.
[0154] As used herein, reference to variable numerical ranges is intended to convey that the application can be implemented with the variable equal to any value within the range. Therefore, for inherent discontinuous variables, the variable can be equal to any integer value within the numerical range, including the endpoints of the range. Similarly, for inherent continuous variables, the variable can be equal to any real value within the numerical range, including the endpoints of the range. For example, a variable described as having a numerical value between 0 and 2 can be 0, 1, or 2 for inherent discontinuous variables, and can be 0.0, 0.1, 0.01, 0.001, or any other real value for inherent continuous variables.
[0155] As used herein, "about" will be understood by one of ordinary skill in the art and will vary to some extent depending on the context in which it is used. If the use of the term is not clear to one of ordinary skill in the art, then in the context in which the term is used, "about" will mean a value within the range of plus or minus 10% of the recited value.
[0156] As used herein, "administering" a compound, formulation, or drug to a subject includes any route of introducing or delivering the compound to a subject to perform its intended function. "Administration" can be performed by any suitable route, including oral, intraocular, ocular, intranasal, parenteral (by intravenous, intramuscular, intraperitoneal, or subcutaneous) or topical administration (such as topical application to the skin of a site such as the eye). "Administration" includes self-administration and administration by another person. Ocular administration or periocular administration can be applied to the subject's affected eye, unaffected eye, or both.
[0157] The term "effective amount" as used herein refers to an amount sufficient to obtain the desired therapeutic and / or preventive effect, such as an amount that causes the prevention or alleviation of a condition associated with an ophthalmic disorder. The amount of the composition administered to the subject will depend on the type and severity of the disease and the nature of the individual, such as normal health, age, sex, weight, and tolerance to the drug. The amount also depends on the extent, severity, and type of the disease. A professional and technical staff will be able to determine the appropriate dosage based on these and other factors. The composition may also be administered in combination with one or more other therapeutic compounds. In the methods described herein, a lipoic acid compound or a pharmaceutical composition containing the same may be administered to a subject with one or more symptoms or signs of an ophthalmic disorder. For example, a "therapeutically effective amount" of lipoic acid or lipoic acid cholinester refers to an average level of the pharmacological effect that minimizes the ophthalmic disorder.
[0158] As used herein, the terms "formulation" and "composition" are used interchangeably and refer to a mixture of two or more compounds, elements, or molecules. In some aspects, the terms "formulation" and "composition" may be used to refer to a mixture of one or more active agents with a carrier or other excipient. A composition can take almost any physical form, including solid, liquid (e.g., solution), or gas.
[0159] In addition, the term "dosage form" may include one or more preparations or compositions provided in a form for administration to a subject. For example, an injectable dosage form may be a preparation or composition prepared in a manner suitable for administration by injection.
[0160] The term "pharmaceutically acceptable" as used herein means a carrier, concentration, or form of drug, etc., approved by regulatory authorities such as CFDA (China), EMEA (Europe) and / or FDA (US) and / or any other national regulatory authorities for use in animals, preferably for use in humans.
[0161] As used herein, the term "simultaneous" therapeutic use refers to the administration of at least two active ingredients (compounds) by the same route and at the same time or essentially at the same time.
[0162] As used herein, the term "separate" therapeutic application refers to the administration of at least two active ingredients (compounds) at the same time or at substantially the same time by different routes.
[0163] As used herein, the term "sequential" therapeutic application refers to administering at least two active ingredients at different times, by the same or different routes of administration. More specifically, sequential application refers to administering one of the active ingredients completely before the administration of the other active ingredient begins. Thus, one active ingredient may be administered several minutes, hours, or days before the other active ingredient is administered. In this case, simultaneous treatment is not performed.
[0164] As used herein, the term "preventing" a disorder or condition refers to a compound that, in a statistical sample, reduces the onset of the disorder or condition in treated samples relative to untreated control samples, or delays the onset of or reduces the severity of one or more symptoms of the disorder or condition relative to untreated control samples.
[0165] Term used herein " related compound " comprises any compound with thioctic acid or thioctic acid choline ester function, as derivative or analog.Those skilled in the art also know how to prepare various thioctic acid related compounds or thioctic acid choline ester related compounds that keep thioctic acid or thioctic acid choline ester function.
[0166] As used herein, the term "derivative" or "analog" of a compound includes any molecule that is functionally and / or structurally related to the compound, such as an acid, amide, ester, ether, acetylated variant, hydroxylated variant, or alkylated variant of the compound. The term derivative also includes structurally related compounds that have lost one or more substituents as listed above. Preferred derivatives of a compound are molecules that have a significant degree of similarity to the compound, as determined by known methods. Similar compounds, along with their similarity indices to the parent molecule, can be found in a large number of databases, such as PubChem (http: / / pubchem.ncbi.nlm.nih.gov / search / ) or DrugBank (http: / / www.drugbank.ca / ). In a more preferred embodiment, the derivative should have a Tanimoto similarity index to the parent drug that is greater than 0.4, preferably greater than 0.5, more preferably greater than 0.6, and even more preferably greater than 0.7. The Tanimoto similarity index is widely used to measure the degree of structural similarity between two molecules. The Tanimoto similarity index can be calculated using software such as Small Molecule Subgraph Detector (http: / / www.ebi.ac.uk / thomton-srv / software / SMSD / ) available online. Preferred derivatives should be related to the parent compound both structurally and functionally, i.e. they should also retain at least some of the activity of the parent drug. Furthermore, the term "derivative" also includes metabolites of the drug, for example, molecules that, after administration to an organism, are produced by (biochemical) modification or processing of the drug, usually by a specialized catalytic system, and which exhibit or retain the biological activity of the drug. Furthermore, the term "derivative" also includes halogenated (e.g., fluoro), protiumated, deuterated, tritiated compounds or combinations thereof in the form of lipoic acid or its salts.
[0167] " derivative " of lipoic acid choline ester is any compound or mixture of compounds except lipoic acid and choline formed by the reaction of lipoic acid choline ester and non-aqueous pharmaceutical excipient. In some embodiments, the derivative is the product formed by the reaction of lipoic acid choline ester and propylene glycol. In certain embodiments, the derivative is the product formed by the reaction of lipoic acid choline ester and glycerol.
[0168] The salt forms of lipoic acid choline ester include all salt forms of lipoic acid choline ester in CN115279745A, including but not limited to lipoic acid choline ester tosylate, lipoic acid choline ester benzene sulfonate, lipoic acid choline ester chloride or lipoic acid choline ester iodide.
[0169] In a specific embodiment, as used herein, "metabolite" refers to a modified or processed drug that retains at least some of the activity of the parent drug, preferably has an inhibitory effect on phosphodiesterase activity or has a therapeutic, preventive, or alleviating effect on myopia and related symptoms. For example, in the body, lipoic acid is reduced to dihydrolipoic acid or oxidized to β-lipoic acid, which is a metabolite of lipoic acid.
[0170] "Extract" refers to a substance extracted or processed from microorganisms, plants or animals (such as all or part of a plant) using appropriate chemical or physical methods, such as solvent extraction or pressing. The substance can be pure, contain a small amount of impurities, or be a mixture.
[0171] "Ophthalmic composition" or "ophthalmic preparation" or "ophthalmic preparation" refers to an ophthalmic composition, or an ophthalmic pharmaceutical composition, or an ophthalmic pharmaceutical product; or a drug, preparation, cosmetic, health product, drug-device combination or device used for the prevention and / or treatment of eye diseases, protection, maintenance, improvement of vision, avoidance, slowing down or reversal of vision damage; or it can be eye drops (eye drops), eye ointments, eye sprays, implants, eye gels, eye patches, eye microspheres, eye sustained-release preparations, periocular injections, intraocular injections, etc.
[0172] "Fish oil" refers to lipid substances derived from higher animals, especially fish (such as cod, salmon), squid, and seal, and specifically refers to the polyunsaturated fatty acids therein, including but not limited to Omega-3 unsaturated fatty acids, DHA, EPA, DPA, ALA, nisinic acid, stearidonic acid, eicosatetraenoic acid, or a combination thereof.
[0173] The active ingredient in the formulation or pharmaceutical composition of the present application is added to water or other suitable solvent deoxygenated to less than 5 ppm with an inert gas, preferably nitrogen, and the preferred deoxygenation level is 2 ppm.
[0174] The administration routes of lipoic acid and its related compounds can be eye drops, injections, instillations and oral administration.
[0175] In terms of specific preparations, the ophthalmic preparation formula includes: cyclodextrin (such as hydroxypropyl β-cyclodextrin), distearate phosphatidylcholine, soybean lecithin, octadecylamine, poloxamer 188, sodium chloride, mannitol, mercaptoethanol, tromethamine, sodium sulfite, ethylenediamine, benzyl alcohol, arginine or any one or a combination thereof.
[0176] The lipoic acid myopia treatment preparation also includes other active ingredients and pharmaceutical excipients, such as reducing agents (glutathione, N-acetylcarnosine), glycerol, propylene glycol, ethyl pyruvate, semifluorinated alkanes, amino acids or their derivatives (such as alanine, methionine, cysteine and histidine), sugars or their metabolites (such as glucose-6-phosphate), oxygen scavengers (such as Oxy-Guard TM or StabilOx TM ), vitamins (vitamin B1, vitamin B2, vitamin C, vitamin E).
[0177] A pharmaceutical composition or formulation containing lipoic acid choline ester having counterions including, but not limited to, chloride, bromide, iodide, sulfate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, hydrogen fumarate, tartrate (optical isomers or mixtures thereof), succinate, benzoate, and glutamate anions; for example, all compositions described in CN109906076A, particularly the compositions described in claims 1 to 9 thereof. In one embodiment, the pharmaceutical composition comprises 0.1-10% of a pharmaceutically acceptable salt of lipoic acid choline ester, 1-30% of a cyclodextrin, 0.1-2% of a tonicity modifier, 0.1-0.5% of a viscosity enhancer, 0.003-0.010% of a preservative, 0.05% to about 1.0% of a biochemical energy source, and water for injection.
[0178] The present disclosure identifies a compound, namely lipoic acid, for use in the treatment, prevention or alleviation of myopia and its related symptoms to enhance myopia reduction or myopia alleviation effects while avoiding or minimizing adverse side effects, such as those observed with atropine therapy.
[0179] The present application relates to pharmaceutical compositions or methods for treating, preventing or alleviating myopia and its related symptoms in individuals, such as infants, school-age children, adolescents or younger adults. In some instances, treating, preventing or alleviating myopia and its related symptoms may comprise administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition or dosage form.
[0180] The pharmaceutical composition or preparation comprises a therapeutically effective amount of lipoic acid or lipoic acid choline ester compound, or a salt thereof, or a related compound thereof.
[0181] In another aspect, the present application provides an ophthalmic device containing a pharmaceutical composition, wherein the pharmaceutical composition comprises lipoic acid or a therapeutically acceptable salt thereof or a derivative thereof, preferably, wherein the ophthalmic device delivers the pharmaceutical composition in a sustained-release manner; preferably, wherein the ophthalmic device delivers the pharmaceutical composition in a pulsed manner.
[0182] Through experiments, we unexpectedly found that the use of lipoic acid or lipoic acid choline ester alone can significantly slow down the process of negative refraction in a guinea pig myopia model induced by form deprivation or lenses, and even completely inhibit (terminate) the process of negative refraction in some individuals, and can significantly inhibit axial elongation. Based on this, it can be confirmed that lipoic acid compounds have the effect of preventing or treating, preventing or controlling the progression of myopia in animals, especially humans, such as infants, school-age children, children and adolescents, minors, people aged 2 to 30 or young adults.
[0183] In some embodiments, the subject of treatment of the technical solution of the present application is a child or adolescent, aged 2-30 years, preferably 6-18 years, or 12-18 years. In some embodiments, the subject of treatment of the technical solution of the present application is an adult, for example, aged 16-65 years, preferably 16-26 years.
[0184] In the topical administration experiment, no discomfort or eye abnormalities were observed in any of the animals administered the drug, nor were there any toxic manifestations such as weight loss or decreased food intake. Based on the existing clinical application of lipoic acid, those skilled in the art can expect that it will have good drug safety in the clinical treatment process of treating, preventing or improving myopia and its related symptoms.
[0185] The pharmaceutical composition of the present application has a technical effect that is significantly superior to atropine in treating, preventing or alleviating myopia and its related symptoms, and no adverse reactions such as eye irritation, pupil dilation, inflammation or allergy were observed in the experiment.
[0186] In certain embodiments of the pharmaceutical compositions, ophthalmic devices, or methods of treatment disclosed herein, the patient is treated for a period of between about 1 month and 20 years, such as a period of at least 6 months, at least 1 year, at least 2 years, at least 3 years, at least 5 years, at least 7 years, or at least 9 years.
[0187] In other embodiments, the pharmaceutical composition, ophthalmic device, or method of treatment according to any one of the above embodiments and any one or more of the other embodiments herein, wherein the pharmaceutical composition is a topical formulation, such as a topical ophthalmic composition, an ophthalmic gel formulation, an ophthalmic emulsion, an ophthalmic liposome, a nanodisc, a nanoparticle suspension, an ointment or cream, such as an ophthalmic ointment (e.g., an eye ointment), an oral formulation, such as a tablet or capsule or powder or syrup.
[0188] In other embodiments, according to any one of the above embodiments and any one or more of the other embodiments herein, the medicine, preparation, composition, device or method of treatment, wherein the medicine, preparation, composition further comprises one or more other ophthalmologically useful excipients and additives, including carriers, stabilizers, osmotic pressure regulators, preservatives, antioxidants, buffers, tonicity regulators, thickeners or other excipients. In other embodiments, the osmotic pressure regulator is sodium chloride. In other embodiments, the preservative is selected from benzalkonium chloride, cetrimide, sodium perborate, stable oxychloride complex, sofia, polyquaternium-1, chlorobutanol, disodium edetate, polyhexamethylene biguanide or a combination thereof. In other embodiments, the buffer is selected from borate, borate-polyol complex, phosphate buffer, citrate buffer, acetate buffer, carbonate buffer, organic buffer, amino acid buffer or a combination thereof. In other embodiments, the tonicity adjusting agent is selected from sodium chloride, sodium nitrate, sodium sulfate, sodium bisulfate, potassium chloride, calcium chloride, magnesium chloride, zinc chloride, potassium acetate, sodium acetate, sodium bicarbonate, sodium carbonate, sodium thiosulfate, magnesium sulfate, disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, glucose, mannitol, sorbitol, glucose, sucrose, urea, propylene glycol, glycerin, or a combination thereof. In other embodiments, the carrier is selected from, but is not limited to, water, mixtures of water and water-miscible solvents, vegetable or mineral oils containing 0.01% to 5% by weight of hydroxyethylcellulose, ethyl oleate, carboxymethylcellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, ethyl acrylate, polyacrylamide, pectin, alginate, starch derivatives, polyvinyl alcohol, polyvinyl pyrrolidone, polyvinyl methyl ether, polyethylene oxide, cross-linked polyacrylic acid, carbopol, lecithin, polyethylene glycol stearate, polyhydroxy alcohol, acidic cosolvent, heptadecaethyleneoxycetyl alcohol or polyoxyethylene sorbitan monooleate.
[0189] In other embodiments, the medicament, formulation, composition, device or method of treatment according to any one of the above embodiments and any one or more of the other embodiments herein, wherein the medicament, formulation, composition, device or method of treatment comprises a polyhydroxy alcohol and / or an acidic cosolvent, optionally hydroxypropyl-β-cyclodextrin and citric acid or tartaric acid.
[0190] In other embodiments, when it comes to the use of the present application, the prevention and control (treatment) effect of lipoic acid or lipoic acid cholinester, or its optical isomers or racemates, or its solvates, or its pharmaceutically acceptable salts, or its prodrugs, or its metabolites, or its related compounds or extracts, or its crystalline compounds, or a combination of these substances on myopia is not related to the gender, age, myopia type, myopia progression rate and myopia severity of the subject.
[0191] In other embodiments, the pharmaceutical composition, ophthalmic device, or method of treatment according to any one of the above embodiments and any one or more of the other embodiments herein, wherein the pharmaceutical composition is a sustained release formulation or a subconjunctival reservoir (depot); or the pharmaceutical composition is contained in an ophthalmic device, such as an eye patch, suture, corneal contact lens; or the pharmaceutical composition is an ophthalmic composition and / or the ophthalmic composition is contained in an ophthalmic device; or the ophthalmic device is a contact lens, an eye insert, a corneal onlay, a corneal inlay, a nanodisc, a liposome, a nanoparticle, a punctal plug, or a microfluidic reservoir. or the ophthalmic device delivers the pharmaceutical composition in a sustained-release manner; or the pharmaceutical composition is formulated as an ophthalmic composition for the treatment of an ophthalmic disorder or condition; or the pharmaceutical composition is formulated as an ophthalmic composition for the treatment of pre-myopia (or risk of developing myopia), myopia, high myopia, moderate myopia, low myopia, true myopia, pseudomyopia, or myopia progression; or the pharmaceutical composition is substantially uniformly distributed throughout the ophthalmic device; or the ophthalmic device is contained within a contact lens blister pack, or wherein the pharmaceutical composition is immersed within an ophthalmic device within a contact lens blister pack.
[0192] Pharmaceutical formulation forms, modes of administration, and dosages: Cells, organs, or tissues can be contacted with lipoic acid or its related compounds using any method known to those skilled in the art. Suitable methods include in vitro, ex vivo, or in vivo methods. In vivo methods typically include administering the lipoic acid compound of the present application or a pharmaceutical composition containing it to a mammal, preferably a human. When used in vivo for treatment, the lipoic acid compound or a pharmaceutical composition containing it can be administered to the subject in an effective amount (i.e., an amount with the desired therapeutic effect). The dosage and dosing regimen will depend on the extent of the ophthalmic condition in the subject, the subject, and the subject's medical history.
[0193] Unlike brand-new compounds, lipoic acid (or lipoic acid choline ester) is an old drug that has been used clinically for many years. Those skilled in the art can determine the "boundary" of compounds equivalent to lipoic acid (or lipoic acid choline ester) based on the existing technology and the description of the instructions, and are able to use appropriate "its optical isomers or racemates, or solvates, or pharmaceutically acceptable salts or esters, or prodrugs, or metabolites, or related compounds or extracts, or crystalline compounds thereof" to achieve the purpose of this application. For example, with respect to different forms of compounds, compound salt formation is a conventional technology in the art, and various salts of compounds are generally considered to have similar functions to the original compounds (such as Ye Xuan et al., Case Analysis of Salt Modification in New Drug Research and Development, Chinese Journal of New Drugs, 2019, Vol. 28, No. 19, pp. 2332-2335); the optical isomers or racemates of the compound, or its crystalline compounds all have exactly the same molecular structure and composition as the compound, and in the absence of contrary evidence, people generally recognize that these compounds all have similar functions. Regarding solvates, the specification exemplarily describes that lipoic acid (or lipoic acid choline ester) dissolved in physiological saline, DMSO, PEG, and Tween as solvents can be used to treat myopia (see Example 1).
[0194] The compounds disclosed herein may also exist as prodrugs. Prodrugs of the compounds described herein are modified forms that are susceptible to chemical changes under physiological conditions to obtain lipoic acid or its related compounds. In addition, prodrugs can be converted into the compound in an isolated environment by chemical or biochemical methods. For example, when placed in a transdermal patch reservoir (reservoir) with a suitable enzyme or chemical reagent, the prodrug can be slowly converted into the compound. Prodrugs are generally useful because, in some cases, they may be easier to administer than the compound or parent drug. For example, they can be bioavailable by oral administration, while the parent drug cannot. The solubility of the prodrug in the pharmaceutical composition may also be higher than that of the parent drug. Many prodrug derivatives are known in the art, such as prodrug derivatives that rely on the hydrolytic cleavage or oxidative activation of the prodrug. A non-limiting example of a prodrug is a compound that is administered as an ester ("prodrug") but then metabolically hydrolyzed into a carboxylic acid (active entity). For example, lipoic acid choline ester chloride is a prodrug of lipoic acid. Chloride is in the form of a salt. Choline ester can help the compound penetrate into the cornea. When or after lipoic acid choline ester chloride enters the cornea, lipoic acid choline ester chloride is hydrolyzed into choline and lipoic acid.
[0195] The compounds disclosed herein may exist as therapeutically acceptable salts. This application includes the above-listed compounds in salt form, including acid addition salts. Suitable salts include salts formed with organic and inorganic acids. Such acid addition salts are generally pharmaceutically acceptable. However, non-pharmaceutically acceptable salts may be used to prepare and purify problematic compounds. Base addition salts may also be formed and are pharmaceutically acceptable.
[0196] As used herein, the term "therapeutically acceptable salt" refers to a salt or zwitterionic form of a compound disclosed herein that is water-soluble or oil-soluble or dispersible and therapeutically acceptable, as defined herein. Salts can be prepared during the final separation and purification of the compound, or individually prepared by reacting the compound in the form of an appropriate free base with a suitable acid. Representative acid addition salts include acetate, adipate, alginate, L-ascorbate, aspartate, benzoate, benzenesulfonate (benzenesulfonate, besylate), bisulfate, butyrate, camphorate, camphorsulfonate, citrate, digluconate, formate, fumarate, gentisate, glutarate, glycerophosphate, glycolate, hemisulfate, enanthate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate (isothionate), lactate, maleate , malonate, DL-mandelate, mesitylenesulfonate, methanesulfonate, naphthalenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphonate, citrate, picrate, pivalate, propionate, pyroglutamate, succinate, sulfonate, tartrate, L-tartrate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, para-toluenesulfonate (p-tosylate), and undecanoate. In addition, the basic groups in the compounds disclosed herein can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides. Examples of acids that can be used to form therapeutically acceptable addition salts include inorganic acids (such as hydrochloric acid, hydrobromic acid, sulfuric acid and phosphoric acid) and organic acids (such as oxalic acid, maleic acid, succinic acid and citric acid). Salts can also be formed by coordination of the compounds with alkali metal or alkaline earth metal ions. Thus, the present application includes sodium, potassium, magnesium and calcium salts of the compounds disclosed herein.
[0197] The crystalline forms of lipoic acid include all known types, such as the crystalline forms described by Samuel Golob in the literature (Samuel Golob, Improving Biopharmaceutical Properties of Vinpocetine Through Cocrystallization, J Pharm Sci. 2016 Dec; 105(12): 3626-3633).
[0198] Can be during final separation and purification of compound, by making carboxyl and suitable alkali (as the hydroxide of metal cation, carbonate or bicarbonate) or with ammonia or organic primary, secondary or tertiary amine reaction prepare base addition salt.The positively charged ion of acceptable salt for treatment comprises lithium, sodium, potassium, calcium, magnesium and aluminum and nontoxic quaternary ammonium cation, as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N, N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N, N-dibenzylphenethylamine, 1-diphenylhydroxymethylamine and N, N '-dibenzylethylenediamine.Other representative organic amines that are applicable to form base addition salt comprise ethylenediamine, ethanolamine, diethanolamine, piperidine and piperazine.
[0199] While it is possible to administer the compounds of the present application in the form of a crude chemical, it is also possible to provide them as pharmaceutical formulations. Thus, provided herein are pharmaceutical formulations comprising one or more certain compounds disclosed herein or one or more pharmaceutically acceptable salts, esters, prodrugs, amides or solvates thereof, together with one or more pharmaceutically acceptable carriers thereof and optionally one or more other therapeutic ingredients. A carrier is "acceptable" in the sense that it is compatible with the other ingredients of the formulation and not harmful to the recipient thereof. The appropriate formulation depends on the selected route of administration. Any known techniques, carriers and excipients that are suitable and understood in the art may be used; for example, see Remington's Pharmaceutical Sciences. The pharmaceutical compositions disclosed herein may be produced in any manner known in the art, for example, by conventional mixing, dissolving, granulating, sugar coating, fine grinding, emulsification, encapsulation, embedding or compression processes, and may also be prepared as drug-device combinations.
[0200] Preparations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular and intramedullary), intraperitoneal, transmucosal, transdermal, rectal and topical (including skin, oral, sublingual, ocular, intranasal and intraocular) administration, the most suitable route of which may depend, for example, on the condition and illness of the recipient. Preparations can be conveniently provided in unit dosage form and can be prepared by any method known in the pharmaceutical art. Typically, these methods include the step of combining a compound of the present application or a pharmaceutically acceptable salt, ester, amide, prodrug or solvate thereof ("active ingredient") with a carrier constituting one or more auxiliary ingredients. In general, the active ingredient is uniformly and closely combined with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, the product is shaped into the desired preparation to prepare the preparation.
[0201] Formulations of the compounds disclosed herein suitable for oral administration can be presented as discrete units such as capsules, cachets, or tablets, each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water emulsion or a water-in-oil emulsion. The active ingredient can also be presented as a bolus, electuary, or paste.
[0202] Pharmaceutical formulations for oral use include tablets, push-fit capsules made of gelatin, and sealed soft capsules made of gelatin and a plasticizer (such as glycerol or sorbitol). Tablets can be prepared by compression or molding, optionally with one or more auxiliary ingredients. Compressed tablets can be prepared by compressing a free-flowing form of the active ingredient (such as a powder or granules), optionally mixed with a binder, an inert diluent or lubricant, a surfactant, or a dispersant, in a suitable machine. Molded tablets can be prepared by molding a mixture of a powdered compound moistened with an inert liquid diluent in a suitable machine. Tablets can optionally be coated or scored and can be formulated to provide sustained or controlled release of the active ingredient therein. The dosage of all formulations for oral administration should be appropriate to the purpose of myopia prevention or treatment to be achieved by such administration. Push-fit capsules can contain the active ingredient mixed with a filler (such as lactose), a binder (such as starch), and / or a lubricant (such as talc or magnesium stearate), and optionally a stabilizer. In soft capsules, the active compound can be dissolved or suspended in a suitable liquid (such as fatty oil, liquid paraffin or liquid polyethylene glycol). In addition, a stabilizer can be added. A dragee core with a suitable coating is provided. For this purpose, a concentrated sugar solution can be used, which can optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol and / or titanium dioxide, lacquer solution and a suitable organic solvent or solvent mixture. Dye or pigment can be added to tablets or dragee coatings for identification or in order to characterize the different combinations of active compound dosage.
[0203] Examples of fillers or diluents for oral pharmaceutical preparations such as capsules and tablets include, but are not limited to, lactose, mannitol, xylitol, dextrose, sucrose, sorbitol, compressible sugars, microcrystalline cellulose (MCC), powdered cellulose, corn starch, pregelatinized starch, dextrates, dextran, dextrin, dextrose, maltodextrin, calcium carbonate, dibasic calcium phosphate, tricalcium phosphate, calcium sulfate, magnesium carbonate, magnesium oxide, poloxamers (e.g., polyethylene oxide), methylcellulose, and hydroxypropyl methylcellulose. The filler may have complexed solvent molecules, such as in the case where the lactose used is lactose monohydrate.
[0204] Examples of disintegrants used in oral pharmaceutical preparations such as capsules and tablets include, but are not limited to, sodium starch glycolate, sodium carboxymethylcellulose, calcium carboxymethylcellulose, croscarmellose sodium, povidone, crospovidone (polyvinylpolypyrrolidone), methylcellulose, microcrystalline cellulose, powdered cellulose, low-substituted hydroxypropyl cellulose, starch, pregelatinized starch, and sodium alginate.
[0205] In addition, glidants and lubricants can be used in oral pharmaceutical formulations to ensure uniform blending of excipients during mixing. Examples of lubricants include, but are not limited to, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated vegetable oil, light mineral oil, magnesium stearate, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc, and zinc stearate. Examples of glidants include, but are not limited to, silicon dioxide (SiO 2 ), talcum corn starch, and poloxamer. Poloxamer (or available from BASF Corporation) is an ABA block copolymer in which segment A is a hydrophilic polyethylene glycol homopolymer and segment B is a hydrophobic polypropylene glycol homopolymer.
[0206] Examples of tablet binders include, but are not limited to, gum arabic, alginic acid, carbomer, sodium carboxymethylcellulose, dextrin, ethylcellulose, gelatin, guar gum, hydrogenated vegetable oils, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, copolyvidone, methylcellulose, liquid dextrose, maltodextrin, polymethacrylates, povidone, pregelatinized starch, sodium alginate, starch, sucrose, tragacanth gum, and zein.
[0207] Compounds can be formulated for parenteral administration by injection, such as by bolus injection or continuous infusion. Preparations for injection can be provided as unit dosage forms, such as in ampoules or multidose containers to which preservatives are added. Compositions can take the form of suspensions, solutions or emulsions such as in oily or aqueous vehicles, and can contain preparatons, such as suspending agents, stabilizers and / or dispersants. Preparations can be provided in unit doses or multidose containers, such as sealed ampoules and vials, and can be stored in powder form or in a freeze-dried (lyophilized) state, which only requires the addition of a sterile liquid carrier, such as normal saline or sterile pyrogen-free water, just before use. Ready-to-use injection solutions and suspensions can be prepared from sterile powders, granules and tablets of the types previously described. In a preferred embodiment, the pharmaceutical composition of the present application is in the form of an injection, particularly a syringe. Preferably, the pharmaceutical composition is administered by intraocular injection, more preferably by intravitreal injection into the vitreous body.
[0208] Preparations for parenteral administration include, but are not limited to, aqueous and non-aqueous (oily) sterile injection solutions of the active compound, which may contain antioxidants, buffers, bacteriostats, and solutes that make the preparation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions, which may include suspending agents and thickening agents. Suitable lipophilic solvents or vehicles include fatty oils (such as sesame oil) or synthetic fatty acid esters (such as ethyl oleate or triglycerides) or liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as methylcellulose, sodium carboxymethylcellulose, sorbitol, or dextran. Optionally, such as ethyl oleate or triglycerides) or liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the compound to enable the preparation of high concentration solutions.
[0209] In addition to the aforementioned preparations, the compounds mentioned in this patent, such as lipoic acid, can also be formulated into storage preparations. Such long-acting preparations can be administered by implantation (e.g., subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compound can be formulated with a suitable polymeric material or hydrophobic material (e.g., as an emulsion in an acceptable oil) or an ion exchange resin, or formulated into a slightly soluble derivative, such as a slightly soluble salt.
[0210] For buccal or sublingual administration, the composition may take the form of tablets, troches, lozenges or gels formulated in conventional manner. Such compositions may comprise the active ingredient, such as the compounds mentioned in this patent such as lipoic acid, in a flavored base such as sucrose and gum arabic or tragacanth.
[0211] The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, eg, containing conventional suppository bases such as cocoa butter, polyethylene glycol, or other glycerides.
[0212] In addition to the aforementioned preparations, the compounds mentioned in this patent, such as lipoic acid, can also be formulated into disposable preparations, devices, eye appearance-changing products or medical consumables for local administration, such as single-use eye drops (each package contains only one therapeutically effective dose), individually packaged eye patches, cosmetic contact lenses, and daily disposable contact lenses.
[0213] The compounds disclosed herein, such as lipoic acid, can be administered topically, i.e., by non-systemic administration. This includes applying the compounds disclosed herein to the exterior of the eye, epidermis, or oral cavity, and instilling such compounds into the ear, eye, and nose, so that the compounds do not significantly enter the bloodstream. In contrast, systemic administration refers to oral, intravenous, intraperitoneal, and intramuscular administration.
[0214] Preparations suitable for topical administration include liquid or semi-liquid preparations (such as gels, ointments, lotions, creams, ointments or pastes) suitable for penetrating the skin to reach the site of action and preparations suitable for application to the eyes, ears or noses, such as drops and sprays. The active ingredient for the treatment of myopia may account for, for example, 0.0000001% to 99% w / w (by weight) of the total content of the preparation. In certain embodiments, the active ingredient may account for up to 50% w / w or more. In other embodiments, it may account for less than 1% w / w. In certain embodiments, the active ingredient may account for 0.01% w / w to 1% w / w. In other embodiments, it may account for 0.00001% to 0.001% w / w of the preparation; alternatively, the active ingredient for topical administration may account for, for example, 0.0000001% to 100% w / v (by weight to volume) of the preparation; alternatively, the active ingredient may account for up to 50% w / v or more. In other embodiments, it may account for less than 1% w / v. In certain embodiments, the active ingredient may comprise 0.01% w / v to 1% w / v. In other embodiments, it may comprise 0.00001% to 0.001% w / v of the formulation.
[0215] The gel preparation comprises a preparation in which lipoic acid or its prodrug or its related compounds are connected to a hydrogel. Preferably, the hydrogel in which the lipoic acid or its prodrug is connected to the hydrogel is a biodegradable hydrogel.
[0216] The hydrogel comprises, preferably consists of, at least one polymer, preferably selected from the group consisting of poly(acrylic acid), poly(acrylates), poly(acrylamides), poly(alkoxy) polymers, poly(amides), poly(amidoamines), poly(amino acids), poly(anhydrides), poly(asparagine), poly(butyric acid), poly(caprolactone), poly(carbonates), poly(cyanoacrylates), poly(dimethylacrylamide), poly(esters), poly(ethylene), poly(ethylene glycol), poly(ethylene oxide), poly(ethyloxazoline), poly(glycolic acid), poly(hydroxyethyl acrylate), poly(hydroxyethyloxazoline), poly(hydroxypropylmethacrylamide), poly(hydroxypropyl methacrylate), poly(hydroxypropyloxazoline), poly(iminocarbonate), poly(N-isopropylacrylamide), poly(lactic acid), poly(lactic-co-glycolic acid), poly(lactic-co-glycolic acid). acid), poly(methacrylamide), poly(methacrylate), poly(methyl oxazoline), poly(propylene fumarate), poly(organocyanophosphate), poly(orthoester), poly(oxazoline), poly(propylene glycol), poly(siloxane), poly(urethane), poly(vinyl alcohol), poly(vinylamine), poly(vinyl methyl ether), poly(vinyl pyrrolidone), silicone, ribonucleic acid, deoxyribonucleic acid, albumin, antibodies and fragments thereof, plasma proteins, collagen, elastin, fascin, fibrin, keratin, polyaspartic acid, polyglutamic acid, prolamin, transferrin, cytochrome, flavoprotein, glycoprotein, hemoprotein, lipoprotein, metalloprotein, phytochrome, phosphoprotein, opsin, agar, agarose, alginate, arabinan, arabinogalactan, carrageenan, cellulose, carbomethyl cellulose cellulose), hydroxypropyl methylcellulose and other carbohydrate-based polymers, chitosan, dextran, dextrin, gelatin, hyaluronic acid and its derivatives, mannan, pectin, rhamnogalacturonan, starch, hydroxyalkyl starch, xylan, and copolymers and functionalized derivatives thereof.
[0217] Preferably, the hydrogel is a biodegradable polyethylene glycol (PEG) based hydrogel.
[0218] Preferably, the polyethylene glycol (PEG) is of a single molecular weight or a group consisting of polyethylene glycols of different molecular weights mixed in a certain ratio.
[0219] The hydrogel is a shaped article, preferably in the form of microparticles. More preferably, the hydrogel is in the form of microbeads. Even more preferably, the microbeads have a diameter of 1-1000 μm, more preferably 5-500 μm, more preferably 10-100 μm, and even more preferably 20-80 μm. The bead diameter is measured when the microbeads are suspended in an isotonic aqueous buffer. In a preferred embodiment, the lipoic acid or prodrug thereof attached to the hydrogel is in the form of beads. More preferably, the lipoic acid or prodrug thereof attached to the hydrogel is in the form of microbeads. Even more preferably, the microbeads have a diameter of 1-1000 μm, more preferably 5-500 μm, more preferably 10-100 μm, and even more preferably 20-80 μm. The bead diameter is measured when the microbeads are suspended in an isotonic aqueous buffer. Such hydrogels can be polymerized in various ways, for example, by free radical polymerization, ionic polymerization, or complex formation reactions.
[0220] If the hydrogel is processed by free radical polymerization or ionic polymerization, the at least two raw materials are a cross-linking macromonomer or a cross-linking monomer (which is called a cross-linking agent reagent) and a multifunctional macromonomer (which is called a backbone reagent). The cross-linking agent reagent carries at least two interconnectable functional groups, and the backbone reagent carries at least one interconnectable functional group and at least one chemical functional group that is not used to participate in the polymerization step. Additional diluent monomers may be present or absent. Useful interconnectable functional groups include, but are not limited to, free radical polymerizable groups such as vinyl, vinyl-benzene, acrylate, acrylamide, methacrylate, methacrylamide, and ionically polymerizable groups such as oxetane, azetidine and ethylene oxide. In an alternative preparation method, the hydrogel is generated by a chemical complex formation reaction. In this type of reaction, the raw material is at least one macromolecular raw material having complementary functional groups that undergo reactions such as condensation or addition reactions. In one embodiment, only one macromolecular starting material is used, which is a heteromultifunctional backbone reagent comprising a large number of polymerizable functional groups which may be the same or different.
[0221] In addition to the active ingredients such as lipoic acid, the topical eye, ear and nose preparations of the present application may also include excipients. Excipients commonly used in such preparations include but are not limited to isotonic agents, preservatives, chelating agents, buffers and surfactants. Other excipients include solubilizers, stabilizers, comfort enhancers, polymers, moderators, pH regulators and / or lubricants. Any of the various excipients can be used for the preparation of the present application, including water, water and a mixture of a water-miscible solvent (such as C1-C7 alkanol), a vegetable oil or mineral oil comprising 0.5% to 5% non-toxic water-soluble polymers, natural products (such as alginate, pectin, tragacanth gum, karaya gum, guar gum, xanthan gum, carrageenan, agar and gum arabic), starch derivatives (such as starch acetate and hydroxypropyl starch) and other synthetic products (such as polyvinyl alcohol, polyvinyl pyrrolidone, polyvinyl methyl ether, polyethylene oxide, preferably a mixture of cross-linked polyacrylic acid and these products). The concentration of the excipient is generally 1 to 100,000 times the concentration of the active ingredient.In preferred embodiments, the excipients to be included in the formulation are generally selected based on their inertness toward the active ingredient component of the formulation.
[0222] For eye, ear and nasal preparations, suitable isotonicity adjusting agents include but are not limited to mannitol, dextrose, sodium chloride, glycerol, sorbitol and the like. Suitable buffers include but are not limited to phosphates, citrates, borates, acetates and the like. Suitable surfactants include but are not limited to ionic and nonionic surfactants (although nonionic surfactants are preferably polysorbate 80, RLM 100, POE 20 cetyl stearyl ether (such as CS20) and poloxamer (such as F68). The preparation may contain substances that increase the viscosity of the solution or suspension, such as sodium carboxymethylcellulose, hypromellose, microcrystalline cellulose, sorbitol or dextran. Optionally, the preparation may also contain suitable stabilizers or agents that increase the solubility of the compound to enable the preparation of high concentration solutions, which include but are not limited to ethanol, benzyl alcohol, polyethylene glycol, phenylethyl alcohol and glycerol.
[0223] The formulations provided herein may contain one or more preservatives. Examples of such preservatives include benzalkonium chloride, parabens, sodium perborate, sodium chlorite, alcohols (such as chlorobutanol, benzyl alcohol, or phenylethyl alcohol), guanidine derivatives (such as polyhexamethylene biguanide), sodium perborate, polyquaternium-1, amino alcohols (such as AMP-95), or sorbic acid. In certain embodiments, the formulation itself may be preservative, thereby eliminating the need for a preservative. In certain embodiments, although the formulation itself is not preservative, packaging materials or packaging design may be used to prevent drug deterioration (such as changes in physical and chemical properties and / or changes in biological effects), thereby eliminating the need for a preservative.
[0224] For ocular, otic, or nasal administration, the formulation may be a solution, suspension, or gel. In preferred aspects, formulations for topical administration to the eye or ear in aqueous solutions or suspensions are in the form of drops. Formulations for topical administration to the nose in aqueous solutions or suspensions are in the form of drops, sprays, or aerosols. The term "aqueous" generally refers to aqueous formulations in which the formulation contains >20%, >50%, more preferably >75%, and especially >90% water by weight. These drops can be delivered from single-dose eye drop bottles, which may preferably be sterile, thereby eliminating the need for antibacterial components of the formulation. Alternatively, the drops can be delivered from multi-dose eye drop bottles, which may preferably include a device for extracting any preservatives from the formulation during delivery, such devices being known in the art. Solution and suspension formulations can be administered nasally using a nebulizer. Intranasal delivery of solutions, suspensions, or dry powders may also be facilitated by aerosol systems based on propellants, including but not limited to hydrofluoroalkane-based propellants, or the active pharmaceutical ingredient may be delivered in dry powder form.
[0225] For ocular conditions, the components of the present application may be delivered to the eye as a concentrated gel or similar vehicle or as a dissolvable insert placed beneath the eyelid.
[0226] In a specific embodiment, the preparation of the application is used once a day. However, the preparation can also be configured to use with any frequency of application, including once a week, once every 5 days, once every 3 days, once every 2 days, twice a day, three times a day, four times a day, five times a day, six times a day, eight times a day, per hour or with any higher frequency. According to the treatment plan, this administration frequency is also kept to the persistent period of varying lengths. The persistent period of a specific treatment plan can vary from a single administration to a plan extending to several months or years. Preparations are applied with different dosages, but typical dosage is to use one to two drops at a time, or a considerable amount of gel or other preparations (such as tablets, eye ointments). Those of ordinary skill in the art are familiar with how to determine the treatment plan for specific indications.
[0227] Gels for topical or transdermal administration generally comprise a mixture of a volatile solvent, a non-volatile solvent, and water. In certain embodiments, the volatile solvent component of the buffered solvent system may include lower (C1-C6) alkyl alcohols, lower alkyl glycols, and lower glycol polymers. In further embodiments, the volatile solvent is ethanol. The volatile solvent component is believed to act as a penetration enhancer and also has a cooling effect on the skin as it evaporates. The non-volatile solvent portion of the buffered solvent system is selected from lower alkylene glycols and lower glycol polymers. In certain embodiments, propylene glycol is used. The non-volatile solvent slows the evaporation of the volatile solvent and reduces the vapor pressure of the buffered solvent system. The amount of this non-volatile solvent component, like the volatile solvent, is determined by the drug compound or drug used. When there is too little non-volatile solvent in the system, the drug compound may crystallize due to the evaporation of the volatile solvent, while too much may lead to a lack of bioavailability due to poor release of the drug from the solvent mixture. The buffer component of the buffered solvent system can be selected from any buffer commonly used in the art; in certain embodiments, water is used. Typical ratios of ingredients are about 20% non-volatile solvent, about 40% volatile solvent, and about 40% water. Several optional ingredients may be added to the topical composition. These include, but are not limited to, chelating agents and gelling agents. Suitable gelling agents may include, but are not limited to, semisynthetic cellulose derivatives (such as hydroxypropyl methylcellulose) and synthetic polymers, galactomannan polymers (such as guar gum and its derivatives), and cosmetic agents.
[0228] Lotions include those suitable for application to the skin or eyes. Eye lotions may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for preparing drops. Lotions or liniments for application to the skin may also include an agent (such as an alcohol or acetone) and / or a humectant (such as glycerol) or oil (such as castor oil or peanut oil) to accelerate drying and cool the skin.
[0229] The pharmaceutical compositions of the present application may be creams, ointments (e.g., 3% ointments, creams) or pastes, which are semisolid preparations of the active ingredient for external application. They can be prepared by mixing the active ingredient in finely divided or powdered form, alone or in a solution or suspension in an aqueous or non-aqueous fluid, with an oleaginous or non-oleaginous base with the aid of a suitable machine. The base may include hydrocarbons such as petrolatum, hard paraffin, soft paraffin or liquid paraffin, glycerol, beeswax, metallic soaps; mucilage; oils of natural origin such as fish oil, almond oil, corn oil, peanut oil, castor oil or olive oil; lanolin or its derivatives or fatty acids (e.g., stearic acid or oleic acid) together with an alcohol (e.g., propylene glycol) or macrogol or lanosterol or dihydrolanosterol. The formulation may be admixed with any suitable surfactant, such as anionic, cationic or nonionic surfactants, such as sorbitan esters or their polyethylene oxide derivatives. Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silica, and other ingredients such as lanolin and lanosterol may also be included.
[0230] Drops or sprays can comprise sterile aqueous or oily solutions or suspensions, and can be prepared by dissolving active ingredient in suitable bactericide and / or fungicide and / or any other suitable preservative and in certain embodiments comprising an aqueous solution of a surfactant. The resulting solution can then be clarified by filtration, transferred to a suitable container, which is then sealed and sterilized by autoclaving or keeping for half an hour at 98-100°C. Alternatively, the solution can be sterilized by filtration and transferred to a container by aseptic technique. Examples of bactericides and fungicides suitable for inclusion in drops include azole compounds (such as econazole), phenylmercuric nitrate or phenylmercuric acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%). Suitable solvents for the preparation of oily solutions include glycerol, dilute alcohols and propylene glycol.
[0231] Formulations for topical administration in the mouth (eg, buccal or sublingual) include lozenges containing the active ingredient in a flavored basis such as sucrose and acacia or tragacanth and pastilles containing the active ingredient in a basis such as gelatin and glycerin or sucrose and acacia.
[0232] For administration by inhalation, the compounds such as lipoic acid mentioned in this patent can be conveniently delivered by an insufflator, a nebulizer pressurized pack or other convenient device for delivering aerosol sprays. The pressurized pack can contain a suitable propellant, such as hydrofluorocarbons, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve to deliver a metered amount. Alternatively, for administration by inhalation or insufflation, the compounds according to the present application can take the form of a dry powder composition, such as a powder mixture of the compound and a suitable powder base (such as lactose or starch). The powder composition can be provided in a unit dosage form in, for example, capsules, cartridges, gelatin or blister packs, and the powder can be administered from the above by means of an insufflator or insufflator.
[0233] Preferred unit dosage formulations are those containing an effective dose, as herein recited, or an appropriate fraction thereof, of the active ingredient.
[0234] It should be understood that in addition to the ingredients specifically mentioned above, the above-mentioned formulations may also include other agents conventional in the art for the type of formulation concerned, such as microneedles, formulations suitable for oral or intranasal administration (which may include flavoring agents).
[0235] The compound can be administered orally or via injection at a dose of 0.001 to 200 mg / kg per day. The dosage range for adults and the elderly is generally 5 mg to 1200 mg / day, and for children or adolescents, the dosage should be reduced or maintained unchanged. Tablets or other presentations provided in discrete units can conveniently contain an amount of one or more compounds that is effective at this dose or multiples of this dose, for example, a unit containing 200 mg to 1200 mg, typically about 300 mg to 600 mg, preferably 400 mg.
[0236] The compounds such as the lipoic acid mentioned in this patent can be used in various ways, such as oral administration, topical application or by injection, or systemic administration and topical administration are carried out simultaneously, or systemic administration and topical administration are carried out alternately. The precise amount of the compound applied to the patient is responsible for by the visiting doctor. The specific dosage level for any particular patient depends on multiple factors, including the activity, age, body weight, general health, sex, diet, application time, route of administration, excretion rate, drug combination, the exact disease of treatment and the indication treated or the order of severity of the symptom of the disease used. In addition, route of administration can be different, and this depends on the symptom of the disease and its order of severity.
[0237] In some cases, it may be appropriate to administer at least one compound described herein (or a pharmaceutically acceptable salt, ester, or prodrug thereof) in combination with another therapeutic agent. By way of example only, if one of the side effects experienced by a patient receiving one of the compounds described herein is hypotension, it may be appropriate to administer an antihypertensive agent in combination with the initial therapeutic agent. Or, by way of example only, the therapeutic effect of one of the compounds described herein may be enhanced by administering an anti-allergic agent (i.e., the anti-allergic agent itself may have only minimal therapeutic benefit, but when combined with the therapeutic agent mentioned herein, the overall therapeutic benefit to the patient is enhanced). Or, by way of example only, the benefit experienced by the patient may be enhanced by administering one of the compounds described herein in combination with another therapeutic agent (which also includes a treatment regimen) that also has therapeutic benefit. By way of example only, in a myopia treatment involving administration of one of the compounds described herein, the therapeutic benefit may be enhanced by also providing the patient with another myopia therapeutic agent. In any case, regardless of the disease, disorder, or condition being treated, the overall benefit experienced by the patient may simply be additive of the two therapeutic agents, or the patient may experience a synergistic benefit.
[0238] Pharmaceutical compositions in dry or liquid form may be provided as single-dose or multi-dose pharmaceutical compositions.
[0239] In one embodiment of the present application, the liquid or dry pharmaceutical composition is provided as a single dose, meaning that the container in which it is provided contains one pharmaceutical dose. Alternatively, the liquid or dry pharmaceutical composition is a multidose pharmaceutical composition, meaning that the container in which it is provided contains more than one therapeutic dose, i.e., the multidose composition contains at least two doses. Such a multidose composition can be used for different patients in need thereof, or can be used for a single patient, wherein after the first dose is applied, the remaining dose is stored until needed.
[0240] In another aspect of the present application, the pharmaceutical composition is in a container. Examples of containers for liquid or dry pharmaceutical compositions include eye drop bottles, syringes, vials, vials with stoppers and seals, ampoules, and cartridges. In particular, the liquid or dry pharmaceutical composition is provided in a syringe. If the pharmaceutical composition is a dry pharmaceutical composition, the container is preferably a dual-chamber syringe. In this embodiment, the dry pharmaceutical composition is provided in a first chamber of the dual-chamber syringe, and the reconstitution solution is provided in a second chamber of the dual-chamber syringe.
[0241] Before applying the dry composition to a patient in need thereof, the dry composition is reconstituted. Reconstitution can be carried out in the container in which the dry composition is provided, for example, in an eye drop bottle, a syringe, a dual-chamber syringe, an ampoule, and a cartridge. Reconstitution is carried out by adding a predetermined amount of a reconstitution solution to the dry composition. The reconstitution solution is a sterile liquid such as water or a buffer, which may contain other additives such as preservatives and / or antimicrobial agents such as benzyl alcohol and cresol. Preferably, the reconstitution solution is sterile water. When the dry composition is reconstituted, it is referred to as a "reconstituted pharmaceutical composition" or "reconstituted pharmaceutical composition" or "reconstituted composition".
[0242] Ophthalmic preparations: The pharmaceutical composition of the present application can be administered in the form of an ophthalmic preparation. The ophthalmic preparation of the present application comprises an ophthalmologically acceptable carrier.
[0243] The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
[0244] As used herein, an "ophthalmically acceptable carrier" is an ophthalmically acceptable solvent, suspending agent, or vehicle for administering a pharmaceutical composition to the eye of a subject. The carrier can be a solid or a liquid. The carrier is "ophthalmically acceptable" in the sense that the carrier is suitable for administration to the eye without causing any significant adverse reaction.
[0245] Typically, ophthalmologically acceptable carriers are or include water. Typically, ophthalmic preparations are in the form of eye drops or gels for application to the eye. Typically, the major part of the preparation is water. Typically, the preparation comprises greater than 50 % by weight (such as greater than 60 % by weight, 65 % by weight, 70 % by weight, 75 % by weight, 80 % by weight, 85 % by weight, or 90 % by weight), more typically greater than 95 % by weight (such as 96 % by weight, 97 % by weight, 98 % by weight, or 99 % by weight) of water.
[0246] In some embodiments, the ophthalmologically acceptable carrier is an oil-in-water emulsion or oil. In such embodiments, the ophthalmic formulation may be in the form of a cream applied to the eye. In such embodiments, the formulation may contain greater than 10% by weight, more typically greater than 20% by weight of an oily component.
[0247] In other embodiments, the carrier may be a biodegradable polymer, such as a biodegradable polymer eye implant for sustained release of the compounds of the present application and optionally other compounds. For example, a biodegradable, biocompatible polymer matrix. In one embodiment, the compound can be embedded in the polymer matrix while maintaining structural integrity. The polymer can be natural, such as a polypeptide, protein, or polysaccharide; or it can be synthetic, such as poly alpha-hydroxy acid. Examples include carriers made from, for example, collagen, fibronectin, elastin, cellulose acetate, cellulose nitrocellulose, methylcellulose, polysaccharides, fibrin, gelatin, and combinations thereof. In one embodiment, the polymer is polylactic acid (PLA) or poly(lactic-co-glycolic acid) (PGLA). The polymer matrix can be prepared and isolated in various forms and sizes, including microspheres and nanospheres.
[0248] In some embodiments, the therapeutic compound is prepared with a carrier that will protect the therapeutic compound from rapid excretion from the body, such as a controlled release agent, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. Such formulations can be prepared using known techniques.
[0249] Excipients: Excipients suitable for use in the ophthalmic formulations of the present application include, for example, demulcents, emollients, tonicity agents, preservatives, buffers, or pH adjusters. Examples of suitable excipients include:
[0250] A. Demulcents: synthetic high molecular weight cross-linked acrylic acid polymers (such as carbomer 974 and carbomer 980); cellulose derivatives (such as hydroxypropyl methylcellulose ("HPMC" or "hydroxypropyl methylcellulose"), hydroxyethyl cellulose, methylcellulose, carboxymethyl cellulose (carboxymethylcellulose)), or sodium carboxymethyl cellulose (sodium carboxymethylcellulose)); dextran (such as dextran 70); gelatin; polyols (such as glycerol, polyethylene glycol 300, polyethylene glycol 400, polysorbate 80, and propylene glycol); polyvinyl alcohol; povidone (polyvinyl pyrrolidone); poloxamers; and hyaluronic acid (a disaccharide polymer) or its sodium or potassium salt.
[0251] B. Softeners: lanolin (such as anhydrous lanolin); oily ingredients (such as light mineral oil, mineral oil, paraffin, petrolatum, liquid paraffin, white ointment, white petrolatum, white wax and yellow wax); and fish oil, castor oil.
[0252] C. Preservatives: benzalkonium chloride; sodium perborate; Oxyd (sodium chlorite 0.05%, hydrogen peroxide 0.01%); polyquaternium-1 (polymer of ethanol, 2,2′,2″-nitrilotris- with 1,4-dichloro-2-butene and N,N,N′,N′-tetramethyl-2-butene-1,4-diamine); sodium silver chloride; hexamethylene biguanide; oxyborate; and (sodium chlorite 0.005% m / v).
[0253] D. Ophthalmic hypertonic agent: sodium chloride.
[0254] E. The ophthalmic preparations of the present application may also contain preservatives to inhibit the growth of microorganisms and extend the shelf life of the preparations. Preservatives that can be used in the ophthalmic preparations of the present application include, for example, benzalkonium chloride, sodium perborate, Oxyd (sodium chlorite 0.05%, hydrogen peroxide 0.01%), polyquaternium-1 (polymer of ethanol, 2,2′,2″-nitrilotris-1,4-dichloro-2-butene and N,N,N′,N′-tetramethyl-2-butene-1,4-diamine), sodium silver chloride, hexamethylene biguanide, and oxyborates. Sodium chlorite (0.005% m / v) is a broad-spectrum antimicrobial Sodium chlorite is a microbicide with very low toxicity to mammalian cells and protects the formulation during storage, but ultimately dissociates into water, sodium ions, chloride ions, and oxygen after exposure to light. Because it is also found in natural tears, the risk of preservative-induced eye irritation and corneal damage is minimized. Sodium chlorite is safe and effective to use in the long term. This preservative has no side effects on epithelial cells in vitro or in vivo, and is less disruptive to cell integrity than many other preservatives currently in use.
[0255] The ophthalmic preparation of the present application can be prepared by any suitable method for preparing an ophthalmic preparation. The ophthalmic preparation is generally sterile, and therefore the method may include a step of sterilizing the ophthalmic preparation. Preferably, the ophthalmic preparation is transparent and has a reflectivity similar to that of tears, a suitable pH (usually buffered to about pH 7.5) to avoid severe corneal irritation and prevent microorganisms. The application's preparation suitable for topical application to the eye is preferably isotonic or slightly hypotonic, so as to counteract any tear hyperosmotic pressure caused by evaporation and / or disease. This may require a tonicity agent to bring the molar osmotic pressure concentration of the preparation to or near the level of 210-320 milliosmoles / kilogram (mOsm / kg). The application's preparation generally has a molar osmotic pressure concentration in the range of 220-320mOsm / kg, preferably with a molar osmotic pressure concentration in the range of 235-300mOsm / kg. Surface tension values close to or lower than the surface tension value of the observed tear film are generally preferred. Ophthalmic preparations are generally formulated into sterile aqueous solutions.
[0256] In certain ophthalmic embodiments, the compositions of the present application are formulated with one or more tear substitutes. Various tear substitutes are known in the art, including but not limited to: monomeric polyols such as glycerol, propylene glycol, and ethylene glycol; polymeric polyols such as polyethylene glycol; cellulose esters such as hydroxypropyl methylcellulose, sodium carboxymethylcellulose, and hydroxypropyl cellulose; dextran such as dextran 70; vinyl polymers such as polyvinyl alcohol; and carbomers such as carbomer 934P, carbomer 941, carbomer 940, and carbomer 974P. The formulations or pharmaceutical compositions of the present application can be used with contact lenses, corneal contact lenses, or other ophthalmic products (such as frame glasses, myopia treatment devices).
[0257] Preferred formulations are prepared using a buffer system that maintains the pH of the formulation between about 4.5 and a pH of about 8. The most preferred formulations have a pH of 5.5 to 7.5. Optional buffers are physiologically tolerated buffers that maintain the pH in the desired range, such as sodium phosphate, bicarbonate, succinate, histidine, citrate, and acetate, sulfate, nitrate, chloride, pyruvate. Antacids such as Mg(OH) or ZnCO can also be used. The buffer capacity can be adjusted to match the conditions most sensitive to pH stability.
[0258] The ophthalmic preparation of the present application may further comprise a cooling agent, such as menthol, camphor, borneol, geraniol, eucalyptol, linalool, etc. When the cooling agent is mixed, the concentration of the cooling agent is preferably 0.0001 to 0.1 W / V%.
[0259] The ophthalmic preparations of the present application may further comprise other commonly used therapeutic components in ophthalmology, such as decongestants (e.g., epinephrine, epinephrine hydrochloride, ephedrine hydrochloride, tetrahydrozoline hydrochloride, naphazoline hydrochloride, naphazoline nitrate, phenylephrine hydrochloride, dl-methylephedrine hydrochloride, etc.), anti-inflammatory / astringents (e.g., neostigmine methylsulfate, ε-aminocaproic acid, allantoin, berberine hydrochloride hydrate, berberine sulfate hydrate, sodium azulenesulfonate, dipotassium glycyrrhizate, zinc sulfate, zinc lactate, lysozyme hydrochloride, etc.), antihistamines (e.g., diphenhydramine hydrochloride, chlorpheniramine maleate, etc.), water-soluble vitamins (e.g., sodium flavin adenine dinucleotide, cyanocobalamin, Pyridoxine hydrochloride, panthenol, calcium pantothenate, sodium pantothenate, etc.), amino acids (such as potassium L-aspartate, magnesium L-aspartate, potassium and magnesium L-aspartate (equal amounts of mixture), aminoethylsulfonic acid, etc.), ingredients that relieve visual fatigue and / or dry eyes (such as taurine, vitamin A, hydroxypropyl methylcellulose and vitamin E), polyunsaturated fatty acids (such as fish oil, omega-3 unsaturated fatty acids, DHA, EPA), piracetam, sulfonamides, niacin, tretinoin, lutein, salidroside, formononetin, atropine, dibazole, M receptor blockers (such as blockers or antagonists or inhibitors for M1 receptors), etc.
[0260] Active substance content of the pharmaceutical composition of the present application: When the drugs are mixed, the concentration of the therapeutically active compound can be selected to be an effective and suitable amount of each substance. Considering the irritation to the eye, the stability of the preparation, etc., the therapeutically active compound (such as lipoic acid) in the pharmaceutical composition can be present in a high concentration, a medium concentration or a low concentration, for example, about 0.0000001-100%, about 0.00001-10%, about 0.001-20%, about 0.1-30%, about 1-40%, about 10-50%, about 20-60% of the total amount of the pharmaceutical composition. , about 30-70%, about 40-80%, about 50-90% (W / V), for example, about 1 μM, about 0.1 μM, about 0.01 μM, about 5 μM, about 10 μM, about 15 μM, about 25 μM, about 50 μM, and / or at least: about 0.0000001%, about 0.000001%, about 0.00001%, about 0.0001%, about 0.001%, about 0.01%, about 0.05%, about 0.1%, about 0.15%, about 1%, or about 10% (W / V) of the total amount of the pharmaceutical composition.
[0261] Delivery of ophthalmic formulations: The ophthalmic formulations of the present application can be delivered to the patient in the form of eye drops (in the form of single-dose or multi-dose droppers), ointments, gels, creams or biodegradable polymer eye implants (designed for sustained release) or by ocular wetting (such as multi-dose sprays).
[0262] The packaging of ophthalmic preparations should be related to the retention or non-retention properties of the solution. Packaging methods such as form-fill-seal technology, which combines blow molding, aseptic filling and sealing into a single process, are particularly useful for packaging preservative-free preparations in unit-dose containers. Typically, these single-dose containers are composed of low-density polyethylene or polypropylene and include a twist-off cap.
[0263] The formulations and methods of the present application are intended for use in any subject that can benefit from the formulations and methods of the present application. The subject is typically a mammal, more typically a human. However, the present application is not limited to treating humans and may be applicable to veterinary use. Therefore, according to the present application, the terms "subject," "patient," or "subject in need" include humans as well as non-human animals, including, for example, farm animals such as sheep, pigs, cows, and horses; pet animals such as dogs and cats; and laboratory animals such as mice, rats, and rabbits. In a preferred embodiment, the mammal is a human.
[0264] In another aspect, the lipoic acid or lipoic acid choline ester, or its optical isomers or racemates, or its solvates, or its pharmaceutically acceptable salts or esters, or its prodrugs, or its metabolites, or its related compounds or extracts, or its crystalline compounds, or a combination of these substances in the present application is used to treat myopia and its related symptoms, or correct myopia, or delay the progression of myopia, mainly by inhibiting the elongation of the axial length, the increase in the vitreous cavity depth and / or the reduction in the choroidal thickness in individuals with myopia or myopia tendency.
[0265] In another aspect, the present application provides an ophthalmic device containing a pharmaceutical composition comprising lipoic acid or lipoic acid choline ester, or a therapeutically acceptable salt thereof or a derivative thereof or a combination thereof, preferably, wherein the ophthalmic device delivers the pharmaceutical composition in a sustained release manner.
[0266] In certain embodiments of the pharmaceutical compositions, ophthalmic devices, or methods of treatment disclosed herein, the pharmaceutical compositions are formulated as ophthalmic compositions, eg, as ophthalmic compositions for the treatment of ophthalmic disorders or conditions.
[0267] In certain embodiments of the pharmaceutical compositions, ophthalmic devices, or methods of treatment disclosed herein, the pharmaceutical composition is substantially uniformly distributed throughout the ophthalmic device.
[0268] In certain embodiments of the pharmaceutical compositions, ophthalmic devices, or methods of treatment disclosed herein, the pharmaceutical composition is administered to the patient's eye; or the pharmaceutical composition is administered topically; or the pharmaceutical composition is administered to the eye in the form of an eye drop formulation, an eye spray formulation, or an eye gel formulation; or the pharmaceutical composition is administered to the eye in the form of an ophthalmic emulsion, an ophthalmic liposome, a nanodisc, a nanoparticle suspension, or an ophthalmic ointment; the pharmaceutical composition is ophthalmically administered to the patient's eye.
[0269] In certain embodiments of the pharmaceutical compositions, ophthalmic devices, or methods of treatment disclosed herein, the pharmaceutical composition is administered 1, 2, 3, 4, or 5 times per day.
[0270] In certain embodiments, the pharmaceutical compositions disclosed herein can be ophthalmic preparations or aqueous compositions, such as ophthalmic aqueous preparations, such as in the form of eye drops. For example, ophthalmic aqueous preparations as described herein can be packaged in eye drop bottles and administered as drops. In certain embodiments, ophthalmic aqueous preparations can be administered as a single administration (i.e., a single dose), which can include one, two, three, or more drops instilled into the patient's eye. In certain embodiments, one dose of an ophthalmic aqueous preparation as described herein is one drop of an aqueous composition from the eye drop bottle.
[0271] In certain embodiments, the pharmaceutical compositions disclosed herein can be ophthalmic gel formulations. For example, the ophthalmic gel formulations can be packaged in eye drop bottles and administered as drops. In certain embodiments, the ophthalmic gel formulations can be administered as a single administration (i.e., a single dose), which can include one, two, three, or more drops instilled into the patient's eye. In certain embodiments, one dose of the ophthalmic gel described herein is one drop of the gel composition from the eye drop bottle.
[0272] In certain embodiments, the pharmaceutical compositions disclosed herein can be ophthalmic ointment formulations. For example, the ophthalmic ointment formulation can be packaged in a tube or other squeezable container having a dispensing nozzle through which a strip of ointment is delivered. In certain embodiments, the ophthalmic ointment formulation can be administered as a single administration (i.e., a single dose) that can include one or more strips that enter the patient's eye. In certain embodiments, one dose of ophthalmic ointment is a strip of ointment composition dispensed through a dispensing tube nozzle.
[0273] Treatment of a subject with a therapeutically effective amount of a therapeutic composition or formulation described herein can include a single treatment or a series of treatments.
[0274] In certain embodiments of the pharmaceutical compositions, ophthalmic devices, or therapeutic methods disclosed herein, the methods prevent, control, or alleviate, slow or reduce the progression of myopia in the treated patient.
[0275] In certain embodiments of the pharmaceutical compositions, ophthalmic devices, or methods of treatment disclosed herein, the methods control, slow, reduce, delay, and / or alleviate myopia progression in a treated patient within the following ranges relative to untreated: between about 5-95%, between about 5-90%, between about 5-80%, between about 5-70%, between about 5-60%, between about 5-50%, between about 5-40%, between about 5-30%, between about 5-20%, between about 10-100%, between about 20-90%, between about 30-90%, between about 40-90%, between about 50-90%, or between about 75-90%.
[0276] In certain embodiments of the pharmaceutical compositions, formulations, ophthalmic devices, or methods of treatment disclosed herein, use of the pharmaceutical compositions, formulations, ophthalmic devices, or methods of treatment limits the magnitude of the refractive power loss in the eye of the subject to be administered to about 1.0-6.0D, 1.0-5.0D, 1.0-4.0D, 1.0-3.0D, 1.0-2.0D, less than 6.0D, less than 5.0D, less than 4.0D, less than 3.0D, less than 2.0D, and less than 1.0D.
[0277] In certain embodiments of the pharmaceutical compositions, ophthalmic devices, or therapeutic methods disclosed herein, the methods reverse myopia progression in the treated patient.
[0278] In certain embodiments of the pharmaceutical compositions, ophthalmic devices, or therapeutic methods disclosed herein, the methods prevent, control, slow, reduce, alleviate, delay, and / or reverse axial (or longitudinal) growth of the eye of the treated patient, i.e., elongation of the axial length and / or increase in vitreous cavity length.
[0279] In certain embodiments of the pharmaceutical compositions, ophthalmic devices, or methods of treatment disclosed herein, the pharmaceutical compositions, ophthalmic devices, or methods of treatment control, slow, alleviate, reduce, delay, and / or reverse axial elongation and / or increase in vitreous cavity length in a treated patient (e.g., mild myopia, childhood or adolescent myopia) by about 5-95%, about 5-90%, about 5-80%, about 5-70%, about 5-60%, about 5-50%, about 5-40%, about 5-30%, about 5-20%, about 10-100%, about 20-90%, about 30-90%, about 40-90%, about 50-90%, or about 75-90% relative to untreated.
[0280] In certain embodiments of the medicaments, formulations, compositions, ophthalmic devices or methods of treatment disclosed herein, the methods control, terminate, slow, reduce, delay and / or alleviate the occurrence and progression of myopia in a patient diagnosed with myopia or at risk of developing myopia, increase the choroidal thickness of the patient's eye (e.g., a myopic eye, a pre-myopic eye, or an eye at risk of developing myopia) and / or reduce the axial (or longitudinal) growth rate of the patient's eye (e.g., a myopic eye, a pre-myopic eye, or an eye at risk of developing myopia), that is, the elongation of the axial length and / or the increase in vitreous cavity length are inhibited.
[0281] In certain embodiments of the pharmaceutical compositions, ophthalmic devices, or methods of treatment disclosed herein, the methods control, slow, reduce, delay, and / or alleviate axial (or longitudinal) growth of the eye of a treated patient by between about 5-95%, between about 5-90%, between about 5-80%, between about 5-70%, between about 5-60%, between about 5-50%, between about 5-40%, between about 5-30%, between about 5-20%, between about 10-100%, between about 20-90%, between about 30-90%, between about 40-90%, between about 50-90%, or between about 75-90%.
[0282] In certain embodiments of the pharmaceutical compositions, ophthalmic devices, or treatment methods disclosed herein, the pharmaceutical compositions, ophthalmic devices, or treatment methods prevent, control, slow, reduce, alleviate, alter, delay, and / or reverse myopia in the eye of the treated patient.
[0283] In certain embodiments of the pharmaceutical compositions, ophthalmic devices, or methods of treatment disclosed herein, the pharmaceutical compositions, ophthalmic devices, or methods of treatment result in less severe adverse reactions relative to atropine monotherapy.
[0284] In certain embodiments of the pharmaceutical compositions, ophthalmic devices, or methods of treatment disclosed herein, the pharmaceutical compositions, ophthalmic devices, or methods of treatment produce a smaller increase in pupil size or no effect on pupil size relative to atropine monotherapy.
[0285] In certain embodiments of the pharmaceutical compositions, ophthalmic devices, or methods of treatment disclosed herein, the pharmaceutical compositions, ophthalmic devices, or methods of treatment inhibit the extent to which a normal eye's axial length or refractive power progresses toward myopia relative to atropine monotherapy.
[0286] Example 1: Preparation of main preparation or pharmaceutical composition
[0287] The form deprivation and lens-induced guinea pig myopia model is a classic and well-recognized myopia animal model in the field. It can be used to evaluate the efficacy and safety of myopia treatment drugs. Its construction method is well known to those skilled in the art. The animal modeling and drug administration methods of this application refer to the scientific literature previously published by this research group (Sen Zhang, Invest Ophthalmol Vis Sci. 2019 Jul 1; 60(8): 3074-3083.; Miaozhen Pan, Exp Eye Res. 2021 Jan; 202: 108332.).
[0288] This lipoic acid preparation is a pharmaceutical composition formulated by the inventors using only the compound lipoic acid as the active pharmaceutical ingredient. The α-lipoic acid compound was purchased from MedChemExpress. Without the addition of other pharmaceutical excipients or other active ingredients, the 0.94% lipoic acid eye drop solution is prepared in the following ratio: DMSO (to dissolve the required amount of lipoic acid compound): PEG 300: normal saline = 1:49:50 (volume ratio), with 0.94 grams of α-lipoic acid per 100 ml of the lipoic acid eye drop solution. At room temperature, the lipoic acid preparation is clear, transparent, and uniform in appearance, with no visible suspended matter.
[0289] R-Alpha Lipoic Acid (R.ALA) was purchased from Suzhou Fujilai Pharmaceutical Co., Ltd. The inventors dissolved R.ALA powder in DMSO to create a 100-fold stock solution, which is a yellow, clear, homogeneous, and stable liquid at room temperature. The stock solution was then diluted to create a working solution in the following ratio: stock solution: PEG 300: Tween 80: 0.9% saline = 1:45:5:49. For example, if the final concentration of the R.ALA preparation used in the experiment was 0.4%, the stock solution was prepared at 40%.
[0290] S-Alpha Lipoic Acid (S.ALA) was purchased from Suzhou Fujilai Pharmaceutical Co., Ltd. S.ALA powder was dissolved in DMSO to prepare a 40% stock solution, which was then diluted to prepare a working solution at a ratio of stock solution: PEG 300: Tween 80: 0.9% saline (1:45:5:49). The final concentration of the S.ALA preparation used was 0.4%.
[0291] Dihydrolipoic acid (DHLA) was purchased from MedChemExpress. DHLA powder was first dissolved in DMSO to prepare a 40% stock solution, and then a working solution was prepared at a ratio of stock solution: PEG 300: Tween 80: 0.9% saline = 1:45:5:49. The final concentration of the DHLA preparation used in the experiment was 0.4%.
[0292] Lipoic acid choline ester [R-alpha-Lipoic Acid Choline Ester, LACE] was purchased from Suzhou Fujilai Pharmaceutical Co., Ltd. LACE powder was directly and completely dissolved in 0.9% normal saline to prepare lipoic acid choline ester solution eye drops of the required experimental concentration, for example, 0.5%.
[0293] Emoxypine succinate (ES) was purchased from MedChemExpress and was completely dissolved in 0.9% saline to prepare a preparation with a concentration of 0.37%.
[0294] Pyridoxol hydrochloride (PH) was purchased from Selleck and was completely dissolved in 0.9% saline to prepare a preparation with a concentration of 0.3%.
[0295] Astaxanthin (ASTA) was purchased from Selleck. ASTA powder was dissolved in the following mixed solvents. The final ratio of the solvents in the preparation was DMSO: PEG300: Tween80: 0.9% saline = 1:45:5:49. The final concentration of the ASTA preparation used in the experiment was 0.87%.
[0296] Blueberry Fruit Extract (BFE) was purchased from Selleck. BFE powder was dissolved in the following mixed solvents. The final ratio of each solvent in the preparation was DMSO: PEG300: Tween80: 0.9% saline = 1:45:5:49. The final concentration of BFE used in the experiment was 6%.
[0297] Atropine sulfate (Atropine) was purchased from MedChemExpress and was completely dissolved in 0.9% saline to prepare a 2 mg / ml stock solution, which was then diluted to the required experimental concentration, such as 0.05%.
[0298] The working solutions used in all examples (e.g., formulations containing lipoic acid, its prodrugs, or its metabolites) were stored in a -80°C freezer after aliquoting. A fresh vial was removed from the freezer before each experimental administration to avoid repeated freezing and thawing. All preparation operations were performed in a dark room.
[0299] All other formulations or pharmaceutical compositions described or used herein, not mentioned in the Examples, were prepared and stored according to routine laboratory methods or standards familiar to those skilled in the art. Conventional physical and chemical dissolution aids, such as heating, stirring, and pH adjustment, may be used during the preparation of all formulations and pharmaceutical compositions, as appropriate. No compound precipitation occurred during administration of any of the formulations.
[0300] The examples of this application use healthy guinea pigs (i.e., without underlying diseases such as hypertension, hyperglycemia, eye diseases or abnormalities, etc.) and both males and females are used. The animal experiments of this application have been reviewed and approved by the Experimental Animal Ethics Committee of Wenzhou Medical University.
[0301] Example 2: Lipoic acid can effectively control the progression of myopia in guinea pig form deprivation model (FDM)
[0302] Three-week-old tricolor guinea pigs with obvious ocular disease or abnormalities were culled. Refraction (infrared eccentric photophoresis) and axial length (A-ultrasound) were measured. Animals with a refractive power between 3 and 8 diopter (D), no more than 2 D of anisometropia, and no more than 0.05 mm difference in vitreous depth and axial length were selected. These animals were randomly divided into two groups: a FD+solvent control group (1% DMSO + 49% PEG-300 + 50% saline, by volume) and a FD+0.94% lipoic acid treatment group. At 8:00 AM on the first day of the experiment, the guinea pigs underwent form deprivation using a face mask with the right eye covered (the experimental eye) and the left eye uncovered (the contralateral eye). FD induction continued throughout the lipoic acid efficacy test, with the mask removed only briefly for drug administration or ocular testing (e.g., refraction). After the start of the efficacy experiment, the headgear position was checked at 8 am, 12 pm, 7 pm and before administration every day, and individuals whose headgear fell off more than 3 times during the administration cycle were eliminated. Starting from the day of modeling, the corresponding solvent or drug (lipoic acid preparation) was administered to the experimental eye at 9-10 am every day, and the injection volume was 100 μL. The drug was administered once a day for 2 consecutive weeks. The refractive power and axial length parameters of both eyes of all subjects were tested at the beginning of the efficacy experiment, 1 week after administration and after the last administration. All data collection and processing methods were the same as those published in the laboratory of the inventor (Pan M, Zhao F, Xie B, et al. Dietary omega-3 polyunsaturated fatty acids are protective for myopia. Proc Natl Acad Sci USA 2021 Oct 26; 118(43): e2104689118). The statistical basis was the difference between the experimental eye and the fellow eye of the same subject. This efficacy experiment has been repeated in two batches of test animals, and all experimental results are basically consistent and the conclusions are the same.
[0303] The experimental results showed that the trend of changes in the refractive power and axial length parameters of the animals in the solvent negative control group were consistent with the expectations of the form deprivation myopia model, proving that the myopia model of this experiment was successfully established and can be used to evaluate the efficacy of lipoic acid in myopia intervention. Compared with the solvent control group, the myopia inhibition rates of the lipoic acid drug group after treatment for 1 week and 2 weeks were 42.4% and 21.1%, respectively, and both were statistically different from the solvent negative control group, proving that lipoic acid can significantly inhibit and slow down the process of negative refractive power in myopic individuals, that is, it can effectively delay and control the occurrence and development of myopia (Table 1). At the same time, compared with the solvent group, lipoic acid administration can also significantly inhibit the elongation of the axial length of myopic individuals and slow down the increase in their vitreous cavity depth, and the above indicators are statistically different from the negative control group (see Figure 1). The specific axial length parameters are as follows (mean ± SD): at 1 week after administration, the mean difference in axial length of both eyes of the same model individual in the lipoic acid treatment group and the solvent negative control group (the one eye of the form deprivation myopia-induced eye) was 0.04364 ± 0.03295 mm and 0.09909 ± 0.01868, respectively, and the corresponding mean difference in vitreous cavity depth was 0.0009091 ± 0.027 mm vs. 0.1164 ± 0.03075 mm; at 2 weeks after administration, the mean difference in axial length of both eyes of the same model individual in the lipoic acid treatment group and the solvent negative control group was 0.06364 ± 0.03722 mm and 0.1236 ± 0.03042, respectively, and the corresponding mean difference in vitreous cavity depth was 0.08545 ± 0.02067 mm vs. 0.06182 ± 0.03157 mm (Table 2). In addition, the animals did not show any toxic reactions, eye irritation, or obvious eye abnormalities after lipoic acid administration, and related indicators such as anterior chamber depth, lens thickness, and corneal curvature of the subjects were not affected by the drug (see Figure 2A, B, C). No pupil dilation effect was observed in all animals in the lipoic acid treatment group during the administration period (Figure 2D).
[0304] The above results indicate that lipoic acid can treat myopia and delay the progression of myopia by inhibiting the elongation of the axial length and / or the increase of the vitreous cavity depth in individuals with myopia or myopia tendency.
[0305] Table 1 Lipoic acid can effectively control the progression of negative refraction in myopia models
[0306] Table 2 Lipoic acid can effectively inhibit the deterioration of axial length parameters in myopia models
[0307] Example 3: Lipoic acid can effectively inhibit the reduction of choroidal thickness in FDM guinea pig myopia model
[0308] In Example 2, the choroidal thickness of all eyes of all test animals was detected using Spectralis HRA+OCT (Heidelberg Engineering, Heidelberg, Germany) 30-60 minutes after the last dose (solvent or lipoic acid). The data collection and processing methods were the same as those published in the laboratory of the inventor (Pan M, Zhao F, Xie B, et al. Dietary omega-3 polyunsaturated fatty acids are protective for myopia. Proc Natl Acad Sci USA 2021; 118), and the statistical basis was the difference between the experimental eye and the contralateral eye of the same subject.
[0309] In the solvent-negative control group, choroidal thickness was significantly reduced in the experimental eye compared to the contralateral eye in the same individual. The results showed that the simple use of lipoic acid (in the form of eye drops) significantly inhibited the reduction of choroidal thickness in myopic eyes. In some animals treated with lipoic acid, choroidal thickness was even maintained at the level of normal (contralateral) eyes under drug intervention. Experimental data showed that after drug (lipoic acid) administration, choroidal thickness in the experimental eyes approached the level of choroidal thickness in the normal eye in the same individual (the difference between the two decreased), and statistical results showed a significant difference between the lipoic acid-treated and solvent-treated groups. In summary, lipoic acid can significantly inhibit the reduction of choroidal thickness and slow the trend of choroidal thinning in myopic individuals or those at risk of developing myopia. Furthermore, these results suggest that lipoic acid can treat and correct myopia by inhibiting choroidal thinning in myopic individuals or those at risk of developing myopia.
[0310] In myopic individuals, parallel light rays are refracted by the refractive system of the relaxed eye, with the image focal point falling in front of the retina. When lipoic acid increases the thickness of the choroid in this myopic individual, it shifts the retina toward the lens, ultimately shortening the distance between the image focal point and the retina, or even aligning them. In myopic individuals, this distance between the image focal point and the retina represents the degree of myopia. Lipoic acid can reduce the distance between the image focal point and the retina and inhibit its increase in distance, which in itself reduces or controls myopia. Administration of lipoic acid to myopic individuals results in clearer distance vision in the treated eye and effective improvement in myopic refraction (correcting myopia and reducing myopia severity), including improved distance vision. Therefore, the myopia intervention and treatment (prevention and control) effect of lipoic acid in the present application is not limited to axial myopia, refractive myopia, pathological myopia, simple myopia, pseudomyopia or true myopia, and is also unrelated to factors such as the age, gender, degree of myopia, rate of myopia progression, ethnicity and genetic background, and age of myopia onset of the subject. That is, lipoic acid has a therapeutic and intervention effect on all types of myopia.
[0311] Example 4: Comparison of the effects of lipoic acid, metformin, pyridoxine, astaxanthin, and bilberry extract (anthocyanidin) in treating myopia
[0312] The guinea pig form deprivation model myopia treatment efficacy evaluation system consistent with that described in Example 2 was used to compare the advantages and disadvantages of metformin, pyridoxine, astaxanthin, bilberry extract, and lipoic acid for myopia prevention and control. The administration method was juxtaconjunctival injection, and the experimental groups were set as 0.05% atropine sulfate group (positive control, Atropine), 0.37% metformin succinate group (ES), 0.3% pyridoxine hydrochloride group (PH), 0.87% astaxanthin group (ASTA), 6% bilberry extract group (BFE), and 0.3% R-lipoic acid group (R.ALA). 0.9% saline was used as the negative control group (Control).
[0313] The experimental results showed that the changes in refractive index and axial length parameters in the negative control group were consistent with the expectations of this myopia model, and the positive control drug atropine demonstrated its expected efficacy. These results confirm that the myopia model was successfully established and suitable for evaluating the efficacy of test drugs. As shown in Figure 4, lipoic acid demonstrated the greatest therapeutic effect for myopia during the dosing period (one-week testing). At the end of the dosing period, only atropine sulfate and R-lipoic acid demonstrated significant myopia therapeutic effects; no other test drugs showed statistically significant differences from the vehicle group. Furthermore, lipoic acid significantly outperformed other control drugs, such as pyridoxine, astaxanthin, and bilberry extract, in inhibiting negative refractive index changes in myopic individuals under the same experimental conditions. In terms of refractive index alone, bilberry extract showed no observed therapeutic effect for myopia after topical administration, and even showed a tendency to induce or worsen myopia. The results of the axial length parameters of each experimental group also support the above conclusions (see Figure 5), indicating that lipoic acid can be very effective in inhibiting the elongation of the axial length and the increase in the depth of the vitreous cavity in myopic individuals or individuals with myopia. Among them, whether it is the axial length or the vitreous cavity depth pharmacodynamic evaluation index, the myopia treatment effect of lipoic acid at the two detection time points after administration is significantly better than that of other comparative drugs. Atropine can also effectively control the progression of myopia after administration, but obvious mydriasis occurs after administration (Figure 6), and this adverse reaction limits its clinical application. In summary, the therapeutic effect of lipoic acid on myopia is significantly better than that of other comparative drugs. Therefore, compared with the prior art, lipoic acid is significantly superior to the prior art in terms of treating myopia and inhibiting the elongation of the axial length of myopic individuals, which is unforeseen by those skilled in the art in advance.
[0314] Example 5: Use of a pharmaceutical composition containing lipoic acid in the treatment of myopia
[0315] The efficacy of a bilberry extract + lipoic acid compound preparation for myopia treatment in a guinea pig form deprivation model, consistent with the efficacy evaluation system described in Example 2, was evaluated at different formulation ratios. Administration was by juxtaconjunctival injection. Three experimental groups were included: a bilberry extract (0.05%) and racemic lipoic acid (1%) group (0.05% BFE + 1% DL-ALA), a bilberry extract (1%) and racemic lipoic acid (1%) group (1% BFE + 1% DL-ALA), and a solvent negative control group (control; the solvent for all test compositions in this experiment was 46 parts PEG300 + 5 parts Tween80 + 49 parts 0.9% saline). Racemic lipoic acid (DL-ALA) was purchased from Suzhou Fujilai Pharmaceutical Co., Ltd.
[0316] The experimental results showed that the changes in refractive index and axial length parameters of the animals in the negative control group were consistent with the expectations of this myopia animal model, proving that the myopia model was successfully established and can be used for the efficacy evaluation of the test drug composition. As can be seen in Figure 7, when the content of lipoic acid and bilberry extract in the drug composition was the same (lipoic acid: bilberry extract = 1:1), the drug composition only showed a trend of myopia treatment, but there was no statistical difference in either the refractive index or the axial length index compared with the solvent control group; however, when the proportion of bilberry extract in the compound preparation was reduced while maintaining the lipoic acid concentration, that is, when lipoic acid was used as the main active ingredient or direct active ingredient of the drug composition (lipoic acid: bilberry extract = 20:1), the drug composition significantly inhibited the progression of negative refractive index and axial length in the myopia model. Compared with the case where the ratio of the two in the pharmaceutical composition is 1:1, when lipoic acid is used as the main active ingredient or direct active ingredient of the pharmaceutical composition (lipoic acid: bilberry extract > 1:1), the myopia treatment effect of the preparation is significantly enhanced, and the efficacy evaluation indicators are statistically different from those of the solvent control group.
[0317] These results demonstrate that pharmaceutical compositions containing lipoic acid as the primary active ingredient exhibit greater myopia control efficacy compared to pharmaceutical compositions containing lipoic acid as a non-primary active ingredient. This is also an unexpected effect: by reducing the content of other primary active ingredients in the pharmaceutical composition, for example, the inclusion of lipoic acid as the primary active ingredient in the formulation not only did not reduce the myopia control efficacy but actually significantly improved it. Previously, it was unknown that lipoic acid could be used to treat myopia and produce such significant therapeutic effects. Consequently, there was no motivation to increase the lipoic acid content in pharmaceutical compositions to a level exceeding that of other active ingredients, and consequently, no attempts or considerations to improve pharmaceutical compositions for treating myopia or enhance the use of drug combinations for myopia treatment using this approach.
[0318] Example 6: Lipoic acid choline ester eye drops (chloride salt form) for use in eye drops to delay myopia progression in young individuals
[0319] Using the guinea pig form deprivation model myopia treatment efficacy evaluation system consistent with that described in Example 2, the effects of different concentrations of R-lipoic acid cholinester eye drops (chloride form, LACE) on the myopia prevention and control effect were systematically studied. Among them, the test animals in all groups were administered directly to the eye drops twice a day (once in the morning and once in the afternoon), with 25uL administered each time. The experimental groups were set with two LACE test concentrations of 0.5% and 0.15%, while the 0.05% atropine sulfate group (positive control, Atropine) and the 0.9% saline solvent group (negative control, Control) were used as controls.
[0320] The experimental results showed that changes in refractive index and axial length parameters in the negative control group were consistent with expectations for this myopia model, and the positive control drug atropine demonstrated its expected efficacy. These results confirm that the myopia model was successfully established and suitable for evaluating the efficacy of test drugs. Figure 8-1 shows that lipoic acid choline ester exhibits a positive dose-response relationship in the form-deprivation myopia model. With increasing dosage, the myopia treatment effect became more satisfactory, and the inhibitory effect on axial length elongation in myopic individuals was also stronger. Compared with the vehicle control group, 0.5% lipoic acid choline ester significantly inhibited the progression of negative refractive index and axial length elongation in form-deprivation myopia over the entire dosing period. Furthermore, under eye drop administration, 0.5% lipoic acid choline ester, a prodrug of lipoic acid, also demonstrated superior overall performance in treating myopia in young individuals, particularly in inhibiting the progression of negative refractive index and axial length elongation after prolonged dosing. During the entire administration period, the inventors did not observe drug-induced mydriasis in the animals in the lipoic acid cholinester group, and their anterior chamber depth, lens thickness, and corneal curvature indicators were not statistically different from those in the negative control group ( FIG. 8-2 ).
[0321] Non-invasive administration of lipoic acid cholinester can effectively treat myopia and significantly inhibit the elongation of the eye axis in myopic individuals or individuals with myopia, and the drug effect is enhanced as the concentration increases. It is well known that the excessive elongation of the eye axis in myopic individuals is the direct cause of various fundus lesions (such as complications of high myopia) and even complete loss of vision in this group of people. The medical focus of myopia treatment is also to prevent the excessive elongation of the eye axis in myopia. The strong biological effect of lipoic acid cholinester in inhibiting the elongation of the eye axis in the drug treatment of myopia proves its excellence and uniqueness as an effective drug for treating myopia in children and adolescents, simple myopia, primary myopia, progressive myopia and axial myopia. It also suggests that individuals with myopia or myopia tendency should use lipoic acid or lipoic acid cholinester as early as possible to prevent and control the occurrence and development of their myopia to avoid irreversible damage to the patient's vision. In addition, lipoic acid choline ester has been formulated as a 1.5% concentration eye drop as an active ingredient for treating presbyopia. Clinical studies have shown that it has good bioavailability and high safety. During the administration of young individuals in this experiment, all animals in the lipoic acid choline ester group did not show eye abnormalities or mydriasis. This result further proves that lipoic acid or its choline ester type prodrugs are safe and reliable for children or adolescents. At the same time, this study explored the minimum effective dose of lipoic acid choline ester drops for the treatment of myopia, which can provide necessary reference data for subsequent formulation development and clinical application in young populations.
[0322] In summary, from the perspective of efficacy and safety, the risk-benefit ratio of lipoic acid or lipoic acid choline ester in the treatment of myopia is better than that of atropine sulfate (for example, using lipoic acid or lipoic acid choline ester during the day will not cause photophobia similar to the mydriasis caused by atropine during the treatment of myopia). It is particularly suitable for delaying the occurrence and development of myopia in children and adolescents, and for the prevention and control of myopia in school-age people.
[0323] Example 7: Lipoic acid optical isomers and their metabolites can significantly inhibit and slow down the progression of myopia in the guinea pig lens-induced model (LIM)
[0324] Healthy 3-week-old tricolor guinea pigs (both males and females) were excluded from those with eye diseases or abnormalities. After refraction (infrared eccentric photorefractive instrument) and axial length (A-ultrasound) testing, animals with a refractive power between 3 and 8.5 diopter (D) and a binocular anisometropia of no more than 2 D, and a binocular vitreous cavity depth and axial length difference of no more than 0.05 mm were selected and randomly divided into the following five groups:
[0325] 1. Lens-induced + solvent control group (Control): Monocularly wear -4D lenses and administer 100 μL of solvent (DMSO: PEG300: Tween80: 0.9% saline = 1:45:5:49) to the wearing eye daily for 1 week, sample size = 11;
[0326] 2. Lens-induced + R-lipoic acid experimental group (R.ALA): Wearing -4D lenses in one eye and applying 100 μl of 0.4% R-lipoic acid to the wearing eye every day for 1 week, sample size = 15,
[0327] 3. Lens-induced + S-lipoic acid experimental group (S.ALA): Wearing -4D lenses in one eye and applying 100 μl of 0.4% S-lipoic acid to the wearing eye every day for 1 week, sample size = 13,
[0328] 4. Lens-induced + dihydrolipoic acid (DHLA) experimental group: Wearing -4D lenses in one eye and applying 100 μL of 0.4% dihydrolipoic acid to the wearing eye daily for 1 week, sample size = 14;
[0329] 5. Lens-induced + positive control group (Atropine): Wearing -4D lenses in one eye and administering 100 μL of 0.05% atropine sulfate to the wearing eye daily for 1 week, sample size = 13;
[0330] Among them, the difference between the negative control group (solvent control group) and the other experimental groups is that it does not contain any active ingredients. Starting from the day of modeling, the corresponding solvent or drug was given to the experimental eye (wearing eye) at 9-10 am every day, and the injection volume was 100 μL per day. The drug was administered once a day for 1 week. The negative mirror induced modeling, peribulbar injection, refractive index and other parameter detection and data processing of all subjects were the same as the previous scheme used by the research group (CN114796205B). The refractive index of the test animals was detected at the beginning, 3 days and end of the LIM model efficacy experiment, and the statistical basis was the difference between the experimental eye (wearing eye) and the contralateral eye of the same subject.
[0331] The experimental results showed that the refractive index changes in the negative control group animals met expectations for the LIM myopia model, and the positive control drug atropine demonstrated expected efficacy. These results confirm that the myopia model was successfully established and suitable for evaluating the efficacy of test drugs. As shown in Figure 9, all test compounds demonstrated significant myopia therapeutic effects throughout the entire dosing period, delaying the decline in refractive index in myopic individuals. However, pupil dilation was observed in the atropine group. At the end of the dosing period, the refractive index differences between the R-lipoic acid and dihydrolipoic acid groups compared to the solvent group were extremely significant. At day 3 of dosing, the R-lipoic acid and S-lipoic acid groups showed essentially identical efficacy, both outperforming the dihydrolipoic acid group, and even surpassing the positive control atropine group on average. Furthermore, Figure 9 clearly demonstrates that R-lipoic acid exerts a strong inhibitory effect on myopia early in its development and maintains this inhibitory effect. This indicates that the excellent myopia prevention and control efficacy of lipoic acid is independent of the severity of myopia or the rate of refractive index deterioration. During administration, neither lipoic acid optical isomers nor dihydrolipoic acid caused eye irritation and had no effect on anterior chamber depth and lens thickness ( FIG10 ).
[0332] It is generally believed that the primary biological activity of lipoic acid is exhibited in the R-form. Furthermore, dihydrolipoic acid is known to have a stronger reducing ability than lipoic acid. However, our experimental results demonstrate that both chiral structures of lipoic acid are effective in treating myopia, with similar efficacy in the early stages of myopia progression. Overall, dihydrolipoic acid is less effective than R-lipoic acid, suggesting that the treatment of myopia with lipoic acid or its metabolites relies on a previously unknown mechanism of action.
[0333] Example 8: Preparations containing lipoic acid for the treatment of myopia
[0334] The therapeutic efficacy of a low-concentration atropine + lipoic acid compound preparation for myopia was evaluated using the same guinea pig form deprivation model myopia treatment efficacy evaluation system as described in Example 2. The compound preparation was administered by juxtabulbar subconjunctival injection. There were three experimental groups: a 0.05% atropine sulfate group (atropine, positive control), a 0.01% atropine sulfate + 0.15% R-lipoic acid (0.01% atropine + 0.15% R.ALA), and a solvent negative control group (control, 0.9% saline). The preparation method of the above-mentioned compound preparation is: be that 15% R-lipoic acid mother liquor (DMSO dissolving) and concentration are that 0.2% atropine sulfate mother liquor (normal saline dissolving) add in the mixed solvent in the following ratio with concentration, the ratio of each component is 15% R-lipoic acid mother liquor: 0.2% atropine sulfate mother liquor: PEG300: Tween80: 0.9% normal saline=1: 5: 45: 5: 44, make this preparation final concentration be 0.01% atropine sulfate+0.15% R-lipoic acid.
[0335] The experimental results show that the changes in the refractive index and axial length parameters of the negative control group animals are in line with the expectations of this myopia animal model, proving that the myopia model of this experiment was successfully established and can be used for the efficacy evaluation of the test drug composition. As can be seen from Figure 11 (A), when the test animals were given a lower concentration of lipoic acid (0.15%) at the same time, the efficacy of 0.01% atropine in the myopia treatment process was comparable to that of 0.05% atropine (both groups had significant differences in refractive index compared with the solvent group, and the statistical difference in the 0.01% Atropine + 0.15% R.ALA group was extremely significant). Even at the end of the administration, the refractive index of the compound preparation was better than that of the 0.05% atropine sulfate group. The myopia treatment efficacy benefits from the effective inhibition of the compound preparation on the elongation of the axial length of the myopic individual eye. It can be clearly observed from Figure 11 (B) that the axial length of the myopic eye of the test animals was significantly inhibited by the compound preparation of atropine + lipoic acid during the entire administration period.
[0336] Atropine sulfate is subject to adverse reactions such as mydriasis, photophobia and "rebound" after drug withdrawal. Only lower concentrations, such as 0.01% and 0.02%, can be used in the clinical treatment of myopia. However, due to the small dosage, the response rate of the drug at this concentration is low, and the myopia prevention and control results are often not very satisfactory. If the therapeutic effect of myopia prevention and control drugs such as atropine can be effectively improved while significantly avoiding the occurrence of its adverse reactions, thereby reducing the overall risk of medication in young or underage populations, it is the goal pursued by those skilled in the art. 0.01% Atropine + 0.15% R.ALA (atropine + lipoic acid) can both reduce the adverse reactions of atropine and increase its effectiveness in treating myopia. The existing technology has never suggested or implied the existence of such a combined drug effect. We unexpectedly discovered that lipoic acid may enhance the myopia treatment efficacy of M receptor inhibitors such as atropine in the form of a synergistic effect between drugs. It is speculated that this is because the two have different myopia treatment intervention targets, or that the pharmacokinetic properties of the active ingredients in the eye are changed, or there are other unknown factors. Furthermore, the pathogenesis of myopia itself is extremely complex, and the above phenomenon requires further in-depth research. However, the potential synergistic effect of lipoic acid in myopia prevention and control, when used in combination with other myopia treatment drugs, deserves attention and utilization in the development of myopia drugs.
[0337] In summary, based on the myopia prevention and control effects demonstrated in this study following co-administration with atropine, and the fact that lipoic acid can effectively treat myopia through a novel, yet unknown, mechanism, we believe that lipoic acid can also be used in combination with other myopia treatment drugs or formulated into pharmaceutical compositions for the treatment and prevention of myopia, particularly in children and adolescents. The concentration, proportion, or efficacy contribution of lipoic acid in such pharmaceutical compositions can be higher, lower, or consistent with that of the other active ingredients.
[0338] Example 9: Lipoic acid cholinester eye drops can effectively increase the choroidal thickness of myopic eyes
[0339] After the experiment, the choroidal thickness of the two control groups and the 0.5% lipoic acid choline ester eye drop group in Example 6 was measured (some animals died during the measurement due to reasons other than the test drug, so the corresponding samples were excluded). The detection and analysis methods were based on the literature previously published by the research group (Sen Zhang, Invest Ophthalmol Vis Sci. 2019 Jul 1; 60(8): 3074-3083).
[0340] As shown in Figure 12, compared to the negative control group, lipoic acid choline ester effectively inhibited choroidal thinning in the form deprivation model, and this therapeutic effect was superior to that of the positive control atropine group. Therefore, lipoic acid choline ester has a significant inhibitory and reversal effect on choroidal thinning in myopic individuals. In summary, these experimental results suggest that lipoic acid choline ester can treat and correct myopia by inhibiting the reduction of choroidal thickness in myopic individuals or those at risk of developing myopia.
[0341] Example 10: Lipoic acid optical isomers and dihydrolipoic acid can significantly inhibit the thinning of choroidal thickness in myopic individuals
[0342] The test animals of Example 7 were used to detect choroidal parameters after the experiment (a few animals died during the measurement due to reasons other than the test drug, so these samples were excluded). Specifically, the choroidal thickness of the LIM myopia model animals was measured after the 7-day drug administration experiment. The choroidal thickness was detected using a modified commercial OCTA (Spectralis HRA+OCT, OCTA, Heidelberg, Germany) that was modified to make it more suitable for animal eyes. The guinea pigs were fully anesthetized before the test. After obtaining the guinea pig OCTA images, the measurement results were quantified using a self-written program (MatLab R2017a, MathWorks) to achieve real-time quantitative detection of the choroidal thickness of the guinea pigs (Sen Zhang, Invest Ophthalmol Vis Sci. 2019 Jul 1; 60(8): 3074-3083).
[0343] The results are shown in Figure 13. Compared to the solvent control group, both lipoic acid optical isomers and dihydrolipoic acid were able to effectively inhibit the reduction of choroidal thickness in myopic individuals, as was the positive control atropine (the choroidal thickness of the experimental eyes approached the choroidal thickness level of the normal eyes in the same individual after drug intervention, i.e., the difference between the two decreased). It is worth noting that both lipoic acid optical isomers and dihydrolipoic acid were more efficient in inhibiting choroidal thinning in myopic individuals than the positive control atropine, especially R-lipoic acid, which was able to significantly increase choroidal thickness in myopic eyes.
[0344] Whether it is a form deprivation model or a negative mirror-induced model, this application reports for the first time that lipoic acid, lipoic acid cholinester, and dihydrolipoic acid can increase the choroidal thickness of myopic eyes. In myopic individuals, parallel light rays are refracted by the refractive system of the relaxed eye and focus in front of the retina. When lipoic acid or its structural analogues increases the choroidal thickness of the myopic individual, the retina moves toward the lens, ultimately resulting in a shortening of the distance between the imaging focus and the retina of the myopic eye. The distance between the imaging focus and the retina is the degree of myopia. Lipoic acid or its structural analogues can shorten the distance between the two or inhibit the increase of the distance between the two in myopic individuals, which in itself reduces the degree of myopia and treats myopia. Giving lipoic acid or its structural analogues to myopic individuals will result in the treated eye obtaining clearer farsightedness, and its myopic refractive state is effectively reduced, including its farsightedness improvement. Therefore, the myopia treatment and intervention effects embodied by lipoic acid or its structural analogs in the present application are not limited to axial myopia, refractive myopia, pathological myopia, simple myopia, pseudomyopia or true myopia, and are also unrelated to factors such as the age, gender, degree of myopia, rate of myopia progression, nationality, age of myopia onset, and cause of myopia of the subject. That is, lipoic acid optical isomers, or their prodrugs (such as lipoic acid choline ester) or their metabolites (such as dihydrolipoic acid) have therapeutic and intervention effects on all types of myopia.
[0345] Considering the long-term and continuous nature of myopia treatment, as well as the fact that most patients are still growing and developing, lipoic acid or lipoic acid choline ester are superior to other compounds in both efficacy and safety. Our results demonstrate that lipoic acid and any of its salt or ester forms (such as lipoic acid choline ester) are effective in treating myopia. They inhibit axial elongation and slow the increase in vitreous depth, thereby controlling the progression of negative refractive power in myopic individuals or those with myopia. Furthermore, lipoic acid and its pharmaceutically acceptable salts or esters (such as lipoic acid choline ester) can significantly increase choroidal thickness and reduce the severity of myopia in myopic individuals. The above-mentioned lipoic acid and its pharmaceutically acceptable salts or esters (such as lipoic acid choline ester) can be used in the treatment, intervention, correction and prevention of myopia in the form of eye drops, eye ointments, eye sprays, eye injections or eye gels, or even oral dosage forms; this application proves that devices, preparations or pharmaceutical compositions containing such compounds (drugs) can be used to control the progression of myopia.
Claims
1. Use of lipoic acid or lipoic acid cholinester, or its optical isomers or racemates, or its solvates, or its pharmaceutically acceptable salts or esters, or its prodrugs, or its metabolites, or its related compounds or extracts, or its crystalline compounds, or a combination of these substances; characterized in that: The purpose is one of the following or two or more at the same time: ①Prevention and / or treatment of myopia and its related symptoms, and / or myopia correction; or ② Combined with orthokeratology lenses or other myopia treatment drugs to control the occurrence and development of myopia; or ③ For myopia intervention treatment or delaying myopia progression; or ④ inhibiting or slowing down the elongation of the eye axis and / or the increase of the depth of the vitreous cavity of myopic individuals or individuals with a tendency to myopia, and increasing the choroidal thickness of myopic individuals or individuals with a tendency to myopia; or ⑤Prevent, slow down, reduce or treat abnormal eye development in children and adolescents associated with refractive error; or ⑥ Enables an individual to obtain clearer distance vision without wearing lenses or relying on vision correction methods than before and / or than without using these lenses or methods; or 7. Inhibit, delay or slow down the process or speed of negative refraction in myopic individuals or individuals with myopia tendency; or ⑧ Used for preparing a drug, preparation, composition or device, wherein the drug, preparation, composition or device is used to achieve at least one of the uses in ①-⑦ above.
2. The use as claimed in claim 1, wherein the administration is systemic such as oral administration, and / or topical administration (eye drops, eye injections, eye implants, skin cream / emulsions applied around the eyes or eye ointments), and / or parenteral administration (such as administration through mucosa, transdermal administration, microneedle administration), and / or non-invasive administration (such as administration using eye sprays).
3. The use according to claim 1 or 2, wherein the medicine, preparation or composition can be an injection, tablet, lyophilized powder injection, capsule, effervescent tablet, chewable tablet, buccal tablet, granule, ointment, syrup, oral solution, aerosol, nasal drops, external preparation, oral preparation, etc.; preferably an ophthalmic dosage form, including but not limited to eye drops (eye drops), eye ointment, eye spray, implant, eye gel, eye patch, eye microsphere, eye sustained-release preparation, periocular injection, intraocular injection; can also be a regular solution, aqueous solution, unsaturated solution, oil-water mixture The invention relates to a composition, suspension, ointment, lotion, cream, drop, granule, spray, ointment, patch, paste, pill, suppository, emulsion, containing cellulose (such as methylcellulose), polyhydroxy alcohol, cyclodextrin (such as hydroxypropyl-β-cyclodextrin), reducing agent (such as glutathione, N-acetylcarnosine), glycerol, liquid paraffin, petrolatum, propylene glycol, ethyl pyruvate, semifluorinated alkane, amino acid or its derivative (such as alanine, methionine, cysteine and histidine), sugar or its metabolite (such as glucose-6-phosphate), oxygen scavenger (such as Oxy-Guard TM or StabilOx TM ), vitamins (such as vitamin B1, vitamin B2, vitamin C, vitamin E), NADPH, dendrimers, nanomaterials, sustained-release materials, liposomes or any combination thereof.
4. The use according to any of the preceding claims, wherein the myopic individual or the individual with myopia tendency is a person medically diagnosed as suffering from myopia; or a child and / or adolescent, preferably a person aged 2 to 30, more preferably a person aged 6 to 18; or a minor, preferably a person whose eyes are still in the growth and development stage; or a school-age person, preferably a person in grades 1 to 12; or a person whose parents are one or both highly myopic; or a person with insufficient hyperopia reserve.
5. The use according to any of the preceding claims, wherein the myopia is refractive myopia or axial myopia; congenital myopia (myopia from birth or before school age), early myopia (under 14 years old), delayed myopia (16-18 years old), late myopia (after adulthood); low myopia (mild myopia), moderate myopia, high myopia (severe myopia), malignant myopia; pseudomyopia, true myopia; children and / or adolescent myopia (preferably aged 2-30 years old, more preferably aged 6-18 years old), minor myopia, adult myopia Myopia, elderly myopia; simple myopia, pathological myopia, complex myopia; axial simple myopia, simple axial myopia; axial myopia in children and / or adolescents (preferably the age of the population is 2-30 years old, more preferably the age of the population is 6-18 years old); axial myopia in school-age and preschool populations; primary myopia, secondary myopia; primary myopia in children and / or adolescents (preferably the age of the population is 2-30 years old, more preferably the age of the population is 6-18 years old); or progressive myopia in children and / or adolescents (preferably the age of the population is 2-30 years old, more preferably the age of the population is 6-18 years old); Age range: 6-18 years old); curvature myopia, index myopia, astigmatism myopia, positional myopia, bending myopia; axial myopia with continuously negative refraction; myopia caused by long-term close-range use of the eyes, myopia and pseudomyopia caused by visual fatigue, negative refraction caused by adverse drug reactions, myopia, myopia caused by reading, myopia caused by using mobile phones and other electronic products, myopia caused by mismatch of refractive media (components), myopia caused by abnormal refractive development, myopia caused by excessive eye growth, myopia caused by unhygienic use of the eyes, myopia caused by various reasons. Myopia in which the imaging focus of objects falls in front of the retina, myopia that is poorly or ineffectively treated with atropine, non-complex myopia, myopia caused by lack of outdoor exercise, accommodative tension myopia, children's myopia, infant myopia, hereditary myopia, myopia dominated by environmental factors, mixed myopia, traumatic myopia, toxic myopia, drug-induced myopia, diabetic myopia, instrumental myopia, spatial myopia, night myopia, other premature infant myopia, diving myopia, hysterical myopia, and temporary myopia that occurs during menstruation, pregnancy, and various eye diseases and systemic diseases.
6. The use according to any of the preceding claims, wherein the myopia-related symptoms refer to complications caused by myopia or axial elongation, such as complications of high myopia, such as floaters, glaucoma, posterior scleral staphyloma, retinal detachment, retinal tear, retinopathy, amblyopia, macular hemorrhage, choroidal neovascularization, choroidal atrophy, macular degeneration or macular lesions, visual field loss, progressive or sudden decrease in vision (especially near vision), eye soreness and / or pain, night blindness, astigmatism, blindness, vitreous liquefaction, vitreous opacity, strabismus, frequent blinking, frequent rubbing of eyes, anisometropia, blurred vision when looking at distant objects, need to squint or partially close the eyelids to see distant objects clearly, headache caused by eye fatigue, inattention caused by myopia, difficulty in vision when driving, especially at night (night myopia), retinal atrophy and degeneration (hemorrhage and holes), subretinal neovascularization, or eyeball atrophy.
7. The use according to any of the preceding claims, wherein the drug, preparation, composition or device further comprises other drugs, compounds or ophthalmic preparations, including but not limited to myopia treatment drugs (such as pirenzepine, muscarinic antagonists, ampicillin, indolepiperamide, timolol maleate, epinephrine, pyrazine, pipenpine, methylamine, closporin, acetylcholinesterase inhibitors, dopamine agonists, γ-aminobutyric acid, naloxone, glucagon, homatropine bromide, retinoic acid, etc.), M receptor blockers (such as blockers or antagonists or inhibitors for M2 or M3 receptors), atropine or atropine sulfate, dibazole, polyunsaturated fatty acids (such as DHA, EPA), homatropine, hyoscine (racemic), scopolamine, tropicamide, 7-methylxanthine, nicotinic acid, piracetam (Piracet am), salvia miltiorrhiza extract, safflower extract, bear bile extract, fish oil, adenosine triphosphate (ATP), smooth muscle relaxant, anti-vasospasm drug, non-selective adenylate antagonist, vasodilator, mydriatic component, congestion removal component, eye muscle (such as ciliary muscle) regulation component, anti-(anti-)inflammatory agent component, astringent component, antihistamine component, anti-allergic agent component, collagen degradation inhibition component, liver protection (avoid or reduce liver toxicity) component, blood-retinal barrier enhancement component (makes it more difficult for compounds to penetrate through the physiological barrier), amino acids, antibacterial agent components, antioxidant components (such as vitamin C, tea polyphenols, glutathione, etc.), sugars, polymers or their derivatives, cellulose or its derivatives, local anesthetic components, amblyopia treatment components, glaucoma treatment components, miRNA and its modifications, therapeutic components for ophthalmic diseases, excipients, etc.
8. The use according to any one of the preceding claims, wherein lipoic acid or lipoic acid cholinester, or its optical isomer or its racemate, or its solvate, or its pharmaceutically acceptable salt or ester, or its prodrug, or its metabolite, or its related compound or extract, or its crystalline compound, or a combination of these substances and one or more drugs for delaying myopia progression and / or myopia treatment drugs are formulated or designed to be administered continuously, or simultaneously, or sequentially, or alternately, or at intervals, or separately.
9. The use according to any of the preceding claims, wherein the related compounds include but are not limited to: all compounds listed in CN115279745A and CN 111315369 A, and salts further formed from lipoic acid or lipoic acid esters, preferably salts of lipoic acid choline ester, including but not limited to lipoic acid choline ester toluenesulfonate, lipoic acid choline ester benzenesulfonate, lipoic acid choline ester chloride or lipoic acid choline ester iodide; or the conjugates of these substances are the compounds in Figure 3; or 6-(benzylthio)-8-[(hydroxyphenylmethyl)thio]octanoic acid, thioamide (1,2-dithiolane-3-pentanamide), 8-(ethyldithio)-6-(phenyldithio)octanoic acid, thioacyl chloride, 5-(1,2-10-dithiolan-3-yl)pentanoic acid acid), 6,8-dimercaptooctanoic acid (dihydrolipoic acid), dihydrolipoate, 5-(1,2-dithiolan-3-yl)pentanoic acid, 5-(1,2-thiaselenolani-5-yl)pentanoic acid, 5-(1,2-thiaselenolan-3-yl)pentanoic acid, 6,8-dimercaptooctanoic acid (dihydrolipoic acid), dihydrolipoate, 5-(1,2-dithiolan-3-yl)pentanoic acid, 5-(1,2-thiaselenolan-3-yl)pentanoic acid, 6,8-dimercaptooctanoic acid.
10. The use according to any of the preceding claims, characterized in that The preparation is an oral product such as a health product, food, dietary supplement, nutritional product, beverage or cosmetic.
11. The use according to any of the preceding claims, characterized in that The device is an instrument, equipment, consumables, system, medical device, health care product or product that changes the appearance of the eye that can release drugs or has drug delivery function or potential drug delivery ability, such as corneal contact lenses, glasses, artificial lenses, sutures, OK lens cleaning (maintenance) systems, eye patches, eye patches, cosmetic contact lenses, microneedles, eye spray systems, eye massagers, eye fumigators, ocular surface drug delivery devices, intraocular drug delivery devices, fundus drug delivery devices, implantable pumps, wearable devices, acupoint massagers, eye relaxation devices, myopia treatment devices or drug-device combinations for myopia prevention and control.
12. The use according to any of the preceding claims, characterized in that Lipoic acid or lipoic acid choline ester, or its optical isomer or racemate, or its solvate, or its pharmaceutically acceptable salt or ester, or its prodrug, or its metabolite, or its related compound or extract, or its crystalline compound, or a combination of these substances, as the sole active ingredient, main active ingredient, or direct active ingredient; And / or: the content or efficacy of lipoic acid or lipoic acid cholinester, or its optical isomer or racemate, or its solvate, or its pharmaceutically acceptable salt or ester, or its prodrug, or its metabolite, or its related compound or extract, or its crystalline compound, or a combination of these substances accounts for less than 1%, or more than 1%, more than 10%, more than 20%, more than 30%, more than 40%, or more than 50%, more than 60%, more than 70%, more than 80%, more than 90%, or 100% of the total active ingredients of the use; And / or: the content, concentration or proportion of lipoic acid or lipoic acid cholinester, or its optical isomer or racemate, or its solvate, or its pharmaceutically acceptable salt or ester, or its prodrug, or its metabolite, or its related compound or extract, or its crystalline compound, or a combination of these substances in the drug, preparation, composition or device is at least 0.001%, or at least 0.05%, or at least 0.15%; And / or: the efficacy of lipoic acid or lipoic acid cholinester, or its optical isomer or racemate, or its solvate, or its pharmaceutically acceptable salt or ester, or its prodrug, or its metabolite, or its related compound or extract, or its crystalline compound, or a combination of these substances accounts for more than 20%, preferably more than 50% of all raw material ingredients or all active ingredients of the use; The percentage (%) may be a mass ratio, a molar ratio, a mass volume ratio, or a contribution rate to the efficacy of the use.
13. The use according to any of the preceding claims, characterized in that The concentration of lipoic acid or lipoic acid cholinester, or its optical isomer or racemate, or its solvate, or its pharmaceutically acceptable salt or ester, or its prodrug, or its metabolite, or its related compound or extract, or its crystalline compound, or a combination of these substances in the drug, preparation, composition or device is 0.001 μM to 100 M, preferably 0.005 μM to 50 M, preferably 1 μM to 1 M, preferably 300 μM to 300 mM, more preferably 1 mM to 200 mM, more preferably 10 mM to 100 mM (such as about 46 mM, i.e. 0.94%); and The concentration or proportion of / or lipoic acid or lipoic acid cholinester, or its optical isomer or racemate, or its solvate, or its pharmaceutically acceptable salt or ester, or its prodrug, or its metabolite, or its related compound or extract, or its crystalline compound, or a combination of these substances in the drug, preparation, composition or device is higher than 0.0005%, preferably higher than 0.025%, preferably higher than 0.05%, more preferably higher than 0.1%, more preferably higher than 1%, and the percentage (%) can be mass / volume concentration (g per 100 ml) or mass percentage or molar (number) ratio.
14. A locally applied medicament, preparation, composition or device for treating myopia or controlling the progression of myopia, characterized in that: The concentration of lipoic acid or lipoic acid cholinester, or its optical isomer or racemate, or its solvate, or its pharmaceutically acceptable salt or ester, or its prodrug, or its metabolite, or its related compound or extract, or its crystalline compound, or a combination of these substances in the drug, preparation, composition or device is 0.001 μM to 100 M, preferably 0.005 μM to 50 M, preferably 1 μM to 1 M, preferably 300 μM to 300 mM, more preferably 1 mM to 200 mM, more preferably 10 mM to 100 mM; And / or: the concentration or proportion of lipoic acid or lipoic acid choline ester, or its optical isomer or racemate, or its solvate, or its pharmaceutically acceptable salt or ester, or its prodrug, or its metabolite, or its related compound or extract, or its crystalline compound, or a combination of these substances in the drug, preparation, composition or device is not less than 0.0001%, preferably not less than 0.001%, preferably not less than 0.01%, more preferably not less than 0.1%, more preferably not less than 0.8%, and the percentage (%) can be mass / volume concentration (g per 100 ml) or mass percentage or molar (number) ratio.
15. A pharmaceutical composition or compound preparation containing at least two active substances, characterized in that: It includes lipoic acid or lipoic acid choline ester, or its optical isomer or racemate, or its solvate, or its pharmaceutically acceptable salt or ester, or its prodrug, or its metabolite, or its related compound or extract, or its crystalline compound, or a combination of these substances and other active substances for treating myopia.
16. The pharmaceutical composition or compound preparation according to claim 15, characterized in that: The amount, concentration and / or efficacy of lipoic acid or lipoic acid cholinester, or its optical isomers or racemates, or its solvates, or its pharmaceutically acceptable salts or esters, or its prodrugs, or its metabolites, or its related compounds or extracts, or its crystalline compounds, or a combination of these substances in the pharmaceutical composition or compound preparation is not lower than the amount, concentration and / or efficacy of any other active substance for treating myopia, and the efficacy is for treating myopia and / or controlling the progression of myopia.
17. The pharmaceutical composition or compound preparation according to claim 15 or 16, characterized in that: The preparations include, but are not limited to, eye drops, eye ointments, eye sprays, implants, eye gels, eye patches, eye microspheres, eye sustained-release preparations, periocular injections, or intraocular injections.
18. An ophthalmic preparation, characterized in that: In the preparation, lipoic acid or lipoic acid choline ester, or its optical isomer or its racemate, or its solvate, or its pharmaceutically acceptable salt or ester, or its prodrug, or its metabolite, or its related compound or extract, or its crystalline compound, or a combination of these substances is used as the direct, sole, or main active ingredient for treating myopia; wherein the concentration of lipoic acid or lipoic acid choline ester, or its optical isomer or its racemate, or its solvate, or its pharmaceutically acceptable salt or ester, or its prodrug, or its metabolite, or its related compound or extract, or its crystalline compound, or a combination of these substances is 0.001 μM to 100 M, preferably 0.005 μM to 50 M, preferably 1 μM to 1M, preferably 300μM to 300mM, more preferably 1mM to 200mM, more preferably 10mM to 100mM; and / or the concentration or proportion of lipoic acid or lipoic acid cholinester, or its optical isomer or its racemate, or its solvate, or its pharmaceutically acceptable salt or ester, or its prodrug, or its metabolite, or its related compound or extract, or its crystalline compound, or a combination of these substances is not less than 0.0001%, preferably not less than 0.001%, preferably not less than 0.01%, more preferably not less than 0.1%, more preferably not less than 0.8%, and the percentage (%) can be mass / volume concentration (g per 100 ml) or mass percentage or molar (number) ratio.
19. The preparation according to claim 18, characterized in that The preparations include, but are not limited to, eye drops, eye ointments, eye sprays, implants, eye gels, eye patches, eye microspheres, eye sustained-release preparations, periocular injections, or intraocular injections.
20. A method as claimed in any preceding claim, characterised in that The content of lipoic acid or lipoic acid choline ester, or its optical isomer or racemate, or its solvate, or its pharmaceutically acceptable salt or ester, or its prodrug, or its metabolite, or its related compound or extract, or its crystalline compound, or a combination of these substances is a therapeutically effective amount.
Citation Information
Patent Citations
Lipoic acid choline ester compositions and methods to generate biocompatible ophthalmic formulations
CN108135842A
Lipoic acid choline ester compositions and methods to stabilize into pharmaceutically relevant drug products
CN109906076A
Compounds, compositions and methods for treatment of eye disorders and skin diseases
CN111315369A
Pharmaceutical compositions of lipoic acid choline ester salts and methods of treatment using same
CN113387923A
Methods and pharmaceutical compositions for treating myopia
CN114796205B
